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Cyclic AMP
Regulation of cAMP levels
Cyclic adenosine 3’,5’-monophosphate
(cAMP) was the first identified second
messenger (1). A large number of studies have
elucidated the fundamental role of cAMP in the
wide range of cellular responses to many
hormones and neurotransmitters. The activity of
two types of enzymes regulates the level of
intracellular cAMP: adenylyl cyclases (ACs)
and cyclic nucleotide phosphodiesterases
(PDEs).
cAMP is generated from ATP by at least
nine closely related AC isoforms (AC1-9) and
two splice variants of AC8 (for a review see
(2)). Each isoform consists of two hydrophobic
domains (with six transmembrane spans) and
two catalytic cytoplasmic domains (C1 and C2)
(Fig. 1). Seven-transmembrane receptors
stimulate the activity of AC through interaction
with the Gα s subunit of heterotrimeric G
proteins, whereas they inhibit AC activity
through interaction with Gαi or βγ subunits (for
a review on G proteins see (3)). AC activity is
subject to other signal transduction pathways as
well. For instance, the intracellular Ca++ pool
directly regulates AC activity (4), either
positively (AC1 and AC8) or negatively (AC5
and AC6). Calcium also indirectly inhibits AC
act ivi ty  through the Ca++-dependent
phosphatase calcineurin (AC9 (5)) and
CaMKinase II (AC3 (6)). Furthermore, PKC
can directly phosphorylate and activate AC2
and AC5 (7), whereas phosphorylation by PKA
may provide a negative feedback loop (AC5 and
AC6 (8,9)). Finally, localization of ACs to
specific sites in the cell creates very local
microdomains of elevated cAMP levels (10,11).
cAMP is hydrolyzed by PDE1, PDE2,
PDE3,  PDE4,  PDE7,  and PDE8
phosphodiesterases (for a review see (12)). PDE
activity is subject to several signalling
pathways. The calcium pathway, through CaM,
potently activates PDE1 (13). Activation of
receptor tyrosine kinase receptors, e.g. the
insulin receptor, induces PDE3 activity in a
wortmannin sensitive manner, suggesting a role
for PI3K (14). Furthermore, phosphorylation of
PDE3 and PDE4 by PKA stimulates their
activity, possibly providing a negative feedback
loop for PKA signalling (15), whereas PDE4 is
inhibited by ERK phosphorylation (16). Finally,
due to PDE activity, cAMP is not freely
diffusible in the cell, and specific localization of
PDE activity regulates cAMP levels in discrete
microdomains (10,11,17-19).
Targets of cAMP
Protein Kinase A
Protein Kinase A (PKA; also known as
cAMP-dependent kinase, or A-kinase) was the
first target of cAMP to be discovered (20). PKA
is expressed in all animal cells, and until
recently it has been thought to account for all
the effects of cAMP. PKA is a serine/threonine
kinase composed of two catalytic (C) subunits,
which are kept in an inactive state when
associated with two regulatory (R) subunits
(21,22). Three different genes encode the
catalytic subunits Cα, Cβ, and Cγ, whereas four
different genes express the regulatory subunits
RIα , RIβ , RIIα , and RIIβ  (23-26). The
heterotetrameric PKA holoenzyme exists in two
forms, the type I holoenzyme, consisting of the
C dimer associated with RIα and RIβ dimers,
and the type II holoenzyme, consisting of the C
dimer with the RIIα and RIIβ dimers. Each R
subunit contains an N-terminal dimerization
domain, two cAMP binding sites (A and B) and
a ‘hinge region’. The cAMP-A domain interacts
directly with the C subunit and is essential for
stable binding of the R subunit to the C subunit.
In addition, two peripheral recognition sites
(PRS1 and 2) on the C subunit are required for
high affinity binding of C to R (27). The cAMP-
B domain does not contact the C subunit, but
functions to modulate access of cAMP to the
cAMP-A domain. The hinge region contains an
autoinhibitory sequence: a pseudo-substrate
sequence (R-R-X-A-X) in the RI subunit, or a
substrate-like sequence (R-R-X-S-X) in the RII
subunit. These sequences directly contact the C
subunits and prevent substrate binding (28).
Binding of cAMP to the cAMP-B domain
induces a conformational change, upon which
the cAMP-A domain becomes accessible to
cAMP. The cAMP-A domain consists of an
eight-stranded β-barrel, and three helices, the
A-, B-, and C-helix. The C-helix functions as a
critical switch that changes conformation upon
binding of either cAMP or the C-subunit,
respectively (29). Binding of cAMP to the
cAMP-A domain presumably results in folding
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Figure 1. Structure of adenylate cyclase. Each AC isoform consists of two hydrophobic domains (with six
transmembrane spans) and two cytoplasmic catalytic domains (C1 and C2). See text for details.
of the C-helix over the cAMP binding site,
resulting in a conformational change which
relieves the autoinhibitory contact between the
regulatory and the catalytic domain. The
catalytic domain dissociates, allowing
phosphorylation of local substrates on serine
sites within the canonical peptide sequence X-
R-R-X-S-X (where X is any amino acid) (30).
In addition to R subunits, free C subunits
are also inhibited in a cAMP-independent
manner by binding to protein kinase inhibitors
(PKIs), which contain a pseudosubstrate
sequence (R-R-Q-A-I) (31,32).
Finally, PKA activity in the cell is spatially
restricted by over 50 different A-kinase
anchoring proteins (AKAPs). These
nonenzymetic scaffolding proteins generally
anchor RII-containing PKA holoenzymes,
although some AKAPs may also bind RI
holoenzymes (33). AKAPs localize inactive
PKA holoenzymes to specific sites in the cell
(for a review see (34)), allowing efficient cAMP
signalling and appropriate substrate selection
upon activation (35). For example, muscle-
specific mAKAP binds both the PKA
holoenzyme and the phosphodiesterase
PDE4D3. Upon an increase in cAMP
concentration, the C subunits dissociate and
phosphorylate PDE4D3, resulting in an increase
in PDE4D3 activity, thus providing a negative
feedback loop (36).
A large number of proteins have been
identified as substrates for PKA. A well studied
target of PKA is the CREB family of
transcription factors, which includes the cAMP
responsive element (CRE)-binding protein
(CREB), the cAMP responsive element
modulator (CREM), and the activating
transcription factor 1 (ATF1). These proteins
directly bind as a dimer to CREs in various
promoters (37). The CREB transactivation
domain is bipartite, consisting of a constitutive
(Q2 domain) and an inducible domain (KID, for
kinase inducible domain) (38). Phosphorylation
on a key acceptor site in the KID domain (S133
in CREB, S117 in CREM, and S63 in ATF1) by
a number of possible kinases, including PKA,
CaMKIV, and Rsk-2, recruits the transcriptional
co-activator CBP and its paralogue p300 (39-
44). Mutation of this phosphorylation site
(S133A) disrupts the activity of CREB (39).
Use of different internal promoters and
differential splicing of CREB and CREM yields
truncated proteins without the key
phosphorylation site or transactivation domain
and therefore may act as repressors, providing a
negative feedback loop (45,46). For instance,
elevated cAMP levels result in increased
transcription from an alternative promoter in the
CREM gene, yielding a truncated transcript
which encodes a protein called Inducible cAMP
Early Repressor (ICER). Subsequently, ICER
binds to a cluster of four CREs in its own
promoter and represses transcription, thus
constituting a negative autoregulatory loop (47).
Cyclic nucleotide-gated cation channels and
pacemaker channels
Direct binding of cAMP or cGMP
modulates the activity of two types of closely
related ion channels: cyclic nucleotide-gated
cation channels (CNG-channels), and
hyperpolarization-activated and cyclic
nucleotide-gated channels (HCN channels, also
known as pacemaker channels). CNG channels
were originally identified in retina and olfactory
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Figure 2. Structure of CNG-channels and HCN-channels. CNG- and HCN-channels contain six transmembrane
domains, a Ca++-CaM binding domain, and a cNMP binding domain which is capable of binding both cAMP and
cGMP. Modified after (48).
tissues. However, recently, widespread
expression of CNG channels has been
demonstrated, particularly in the central nervous
system, but also in heart, kidney, spleen,
pancreas, lung, testis, muscle, liver, and
keratinocytes (49). The functions of CNG-
channels in most of these tissues are not well
understood, but a common property may be the
regulation of the calcium influx. The NCBI
database contains six different human genes
encoding CNG channels, four of which are α-
subunits (CNGA1, 2, 3, and 4) and two of
which are β-subunits (CNGB1 and CNGB3)
(50). α-subunits can form active channels when
expressed alone, whereas β-subunits do not
form active channels when expressed alone, but
can modulate the activity of the α-subunits.
CNG-channels form hetero-oligomers, probably
tetramers, composed of two α-subunits, and two
β-subunits (for reviews see (48,50)). CNG-
channels contain six transmembrane domains, a
C-terminal cytoplasmic cNMP binding domain,
a Ca++/CaM binding region, and a putative pore
region (Fig. 2). Binding of  ligand, i.e. cAMP or
cGMP, to the cNMP binding site increases
conduction of cations. All known CNG-
channels respond to these ligands, but generally
lower concentrations of cGMP than cAMP are
sufficient to open the channel (51,52). The
sensitivity of CNG-channels for cGMP slowly
increases upon repeated ligand stimulation. This
increase of sensitivity is slowed down by
phosphatase inhibitors and accelerated by
purified type I phosphatase, suggesting that
phosphorylation might modulate ligand
sensitivity (53). Indeed, phorbol ester-induced
phosphorylation by PKC of S577 and S579 in
the cNMP binding domain of CNGA3 reduces
the affinity for ligand two- to three-fold (54).
Furthermore, ligand sensitivity of CNG-
channels is negatively modulated by Ca+ +
binding proteins, possibly CaM (for a review
see (55)).
HCN channels were originally identified in
sino-atrial node cells (56-60), which coordinate
pacemaker activity of the heart,  in hippocampal
pyramidal cells, and in photoreceptor cells (61-
64). The HCN channel family consists of four
members, HCN1-4. They are mainly expressed
in brain and in heart ((65) and references
therein). The structure of HCN channels
strongly resembles the structure of CNG
channels (Fig.  2),  embodying six
transmembrane domains (S1-6), a pore loop
between S5 and S6, and a cNMP binding pocket
in the C-terminus (65). Like CNG channels,
HCN channels likely function as a tetramer,
although it is unknown whether they form
homo-  o r  he te ro te t ramers .  Upon
hyperpolarization, HCN channels open,
resulting in Na+ inward current that slowly
depolarizes the membrane until the threshold
for a new action potential is reached. They
determine the time elapsing between successive
Chapter 1; General introduction
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Figure 3. Structure of Epac proteins. See text for details. RBD of Epac1 is putative.
action potentials and therefore control firing
frequency (65). Binding of cAMP or cGMP
enhances channel activity (66-68), although the
affinity is higher for cAMP than for cGMP (65).
How cyclic nucleotides structurally increase
channel activity remains to be established.
Epac
Epac (exchange protein directly activated
by cAMP) proteins were first identified in a
database search for genes encoding a
combination of a cAMP binding domain and a
CDC25 homology domain, which is a motif for
Ras family guanine nucleotide exchange factors
(GEFs) (69,70). The Epac family consists of
two members, Epac1 and Epac2 (also called
cAMP-GEF I and II), which both have GEF
activity towards the Rap family of small
GTPases (see below). Epac1 is widely
expressed but is enriched in kidney, ovary,
thyroid, brain, and skeletal muscle (70). Epac2
is mainly expressed in brain and adrenal gland.
Epac2 is highly homologous to Epac1 (Fig. 3),
but it contains an extra cAMP binding domain
(cAMP-A domain), which has much lower
affinity for cAMP than the second cAMP
binding domain (cAMP-B domain) of Epac2 or
the cAMP binding domain of Epac1 (71). The
function of the cAMP-A domain is unclear, but
it is not necessary for regulation of Epac2 by
cAMP. Both proteins harbor a Dishevelled, Egl-
10, Pleckstrin (DEP) domain, which is
necessary for membrane localization (71-73).
Furthermore, they contain a Ras exchange motif
(REM) domain, an α-helix which likely plays a
structural role and interacts with the GEF
domain (74). Finally, Epac proteins contain a
putative Ras association (RA) domain, which
may be involved in proper localization of Epac
proteins (Bos JL, 2003, in press). Recently, the
crystal structure of the Epac2 regulatory
domain, consisting of both the cAMP binding
domains and the DEP domain, has been
crystallized in the absence of cAMP (75).
Comparison of this structure with the crystal
structure of the regulatory subunit of PKA in
the presence of cAMP revealed a unifying
mechanism of how cAMP activates these
proteins. The most important differences
between the crystal structures are observed in
the phosphate binding casette (PBC; a highly
conserved structure in cNMP binding domains,
which interacts with the phosphate-sugar region
of cAMP) and the orientation of the hinge
region which connects the cAMP binding
pocket and the lid that covers the cAMP binding
pocket (corresponding to the C-helix in the R
subunit of PKA). In absence of cAMP, a
conserved leucine residue in the PBC restricts
the orientation of the hinge in Epac2. This
leucine is positioned opposite of a
phenylalanine residue in the hinge, thereby
preventing the hinge from moving closer to the
cAMP binding domain. Binding of cAMP,
however, results in reorientation of the PBC,
moving the leucine away from the
phenylalanine in the hinge. Subsequently, the
hinge is now able to move closer to the cAMP
binding domain, allowing the lid to fold over
the cAMP binding domain and to interact
directly with cAMP, thus stabilizing the active
state of the protein. In PKA the conformational
change of the R subunit results in dissociation
of the C subunit. Similarly, binding of cAMP to
the cAMP binding domain of Epac may result
in a conformational change which relieves
inhibitory contacts between a short sequence
(V-L-V-L-E; positioned just C-terminally of the
lid) and the catalytic region, which is then
exposed to its substrates.
The Epac-Rap pathway has been
implicated in a number of physiological
processes, including integrin-dependent cell
adhesion to fibronectin (chapter 3), insulin
secretion (76), activation of PLC and
subsequent calcium release (77), calcium
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release and subsequent hormone secretion
(78,79), PI3K and PKB activation (80), and
possibly p70S6K activation (chapter 4). The
exact molecular mechanism of how the Epac-
Rap pathway stimulates these processes awaits
further analysis.
Ras family of small GTPases
The Ras superfamily of small GTPases
presently consists of at least 13 families,
comprising over 100 proteins which share
extensive similarities in their effector domains.
Ras-like small GTPases function as molecular
switches, cycling between GDP- and GTP-
bound forms. The switch is activated by
guanine-nucleotide exchange factors (GEFs),
which interact with the GTPase and induce
release of the bound GDP, allowing the more
abundant GTP to bind (74). Binding of GTP
induces a conformational change in the switch 1
and switch 2 regions, allowing effector proteins
to bind (74). This results in translocation from
the cytoplasm to the cytoplasmic surface of
membranes, subsequent activation of the
effector protein, and induction of signalling
cascades (81,82). The switch is turned off
through hydrolysis of the GTP by the intrinsic
GTPase activity, which is stimulated by GTPase
activating proteins (GAPs) (83-85). The
interaction between the GTPase and its effector
is then abolished, resulting in termination of the
signalling cascade.
Ras
Ras is the best studied member of the Ras
superfamily and therefore the paradigm of small
GTPases in signal transduction. They have been
found to be mutated in 15% of all human
tumors (86). These mutations all rendered a
constitutively active, GTP-bound Ras. The three
Ras proteins (H-Ras, K-Ras and N-Ras) are
95% identical and ubiquitously expressed, and
localize to the plasma membrane (87). H-Ras(-/-)
and N-Ras(-/-) knockout mice, as well as the H-
Ras(-/-)/N-Ras(-/-) double knockout mice are
perfectly viable, whereas K-Ras(-/-) knockout
mice die before birth, indicating that both H-
Ras and N-Ras are dispensable for normal
mouse growth, development, and fertility, while
K-Ras is not only essential but also sufficient
for normal mouse development (88).
Wild-type Ras is activated by a large
variety of extracellular signals, particularly
growth factors. Phosphorylated tyrosine
residues on the cytoplasmic side of single-span
transmembrane receptors recruit adaptor
molecules like Shc and Grb2. In turn, these
proteins bind and thereby translocate the
RasGEF Sos to the plasma membrane, where it
can activate Ras. Furthermore, seven-
transmembrane receptors can activate Ras
through a complex of Gαi, Grb2 and mSos (89),
and possibly via second messengers like
calcium and diacyl glycerol (DAG), which
recruit the RasGRF and RasGRP exchange
factors to the membrane ((90,91); De Rooij,
unpublished results). Ras GTPase activity is
stimulated by p120-RasGAP, neurofibromin,
and possibly members of the Gap1m family
(92-94).
Several Ras effectors have been described,
which all have been implicated in the effects of
Ras on cell proliferation, morphology, and
attachment. The best described Ras effectors are
the members of the Raf family of
serine/threonine kinases (A-Raf, B-Raf, and
Raf1). Most attention has focused on Raf1,
which contains an N-terminal Ras binding
domain (RBD; amino acids 51-131) which is
sufficient for Ras binding. Full activation of
Raf1, however, is complex and requires
phosphorylation and dephosphorylation of
several residues (see below). Compared with
Raf1, regulation of B-Raf seems less complex.
Analysis of human tumors revealed that it can
be fully activated by mutation of a single
residue in the T-loop, which also overcomes the
need for Ras-binding (95).
Another target of Ras is the RalGEF
family, consisting of RalGDS, Rgl, Rlf, and Rgr
(96-99), which all exhibit specific guanine
nucleotide exchange activity towards Ral.
RalGEFs likely play a role in Ras-induced
cellular transformation, since Rlf-CAAX and
Rsc stimulate serum-independent growth in
NIH3T3 cells, and RalGDS cooperates with
Raf1 in focus formation (99-101). Interestingly,
whereas in murine cells the oncogenic
properties of Ras seem to be mediated by the
Raf pathway, in human cells they may be
mediated by the RalGEF pathway (102). It
should be noted however, that in this study a
cell transformation assay was used in which
both the SV40 large and small T antigens and
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the catalytic subunit of telomerase (hTERT)
were overexpressed; thereby the process of cell
transformation might be oversimplified.
Interaction of Ras with the p110 catalytic
subunit of PI3-kinase enhances its lipid kinase
activity (103,104). However, whereas both
endogenous and oncogenic Ras clearly activate
the Raf- and RalGDS family members, the role
of PI3K as an effector of Ras remains a matter
of debate (105). Also, genetic data from
Drosophila suggest that only activated Ras1 is
able to activate PI3K, whereas endogenous
Ras1 does not seem to be involved in PI3K
regulation (106).
Rap
The family of Rap (Ras proximate)
proteins was first identified in a screen for Ras
homologous genes (107,108), and consists of
Rap1A, Rap1B, Rap2A, and Rap2B. Much
attention has focused on Rap1 after it was
identified in a screen for  cDNAs  that could
revert the morphology of K-Ras-transformed
NIH3T3 cells (109). The hypothesis that Rap1
antagonizes Ras by trapping Ras effectors in an
inactive complex through its highly homologous
effector domain dominated the next decade,
especially when it was found that Rap1 indeed
could trap Raf1 in an inactive complex
(110,111) and that overexpression of an
activated Rap1 mutant could interfere with ERK
signalling in fibroblasts (112,113). In contrast,
Rap1 might also be able to activate Ras
effectors (114) and induce cellular
transformation of Swiss 3T3 fibroblasts (115).
However, endogenous Rap1 is unlikely to play
a role in ERK signalling ((116); chapter 2; also
see below). Rather, Rap1 is likely to have a
signalling function independent of Ras.
Recently, Rap1 has been implicated in
integrin activation and cell adhesion ((117-126);
chapter 3). Additionally, in Drosophila Rap1 is
involved in positioning of adherens junctions,
thus regulating cell-cell adhesion (127),
although it remains possible that the effects
observed in this study result from changes in
cell-to-matrix adhesion.
Rap GTPases also regulate hormone
secretion by pancreatic β-cells through
activation of calcium channels that are sensitive
to ryanodine (78,79). In addition, Rap2B may
regulate calcium levels through activation of
phospholipase C (PLCε), resulting in formation
of DAG and inositol 3-phosphate (IP3), which
in turn activates IP3-activated calcium channels
(77,128).
In addition to Epac, Rap1 is activated by a
number of other GEFs (Fig. 4). The first
RapGEF to be identified was C3G (chicken
retrovirus kinase (Crk) SH3-domain-binding
guanine nucleotide releasing factor), which was
initially isolated as a protein binding to the N-
terminal SH3 domain of Crk (129,130). C3G
has been shown to respond to B and T cell
receptor activation (131), insulin and EGF in
Chinese hamster ovary (CHO) cells stably
expressing the insulin and EGF receptors (132),
erythropoietin, and IL-3 (133). C3G
constitutively associates with the SH3 domain
of Grb2, CrkI and CrkII, and Crk-like (Crk-L)
Figure 4. Rap is regulated by common second messengers. Tyrosine kinase signalling, cAMP, calcium (Ca++),
and diacylglycerol (DAG) all activate RapGEFs. Rap is downregulated by a number of RapGAPs, which may be
directly regulated by Gα subunits of large G proteins.
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proteins through its proline-rich sequences
(130). The SH2 domain of Crk proteins in turn
associates with phosphotyrosine proteins,
resulting in membrane recruitment of the Crk-
C3G module. This probably facilitates
phosphorylation of Y504 in C3G, which may
relieve the autoinhibitory effect of a domain
outside the catalytic region (134). C3G-induced
activation of Rap1 may be downregulated by
the E3 ubiquitin ligase Cbl, possibly resulting in
a decrease in cell adhesion (135). Activation of
C3G results in activation of Rap1 but also R-
Ras (136,137). C3G not only activates JNK
through R-Ras (138), but has also genetically
and biochemically been linked to the Ras-ERK
pathway (133,139,140). C3G has been
suggested to be important for cell adhesion,
formation of focal adhesions, and cell migration
(117,121,131,141). Indeed, C3G not only
stimulates cell adhesion through Rap1, but it
can also directly bind to the SH3 domain of
p130 CAS (142). This in turn may activate R-
Ras, resulting in phosphorylation of p130CAS
and focal adhesion kinase, thus promoting focal
adhesion formation (143).
The PDZ-GEF family consists of two
family members (144-147) which both contain a
PSD-95, Dlg, ZO-1/2 (PDZ) domain, a putative
Ras association (RA) domain which may
interact with active Rap1 or M-Ras (148-150), a
Ras exchange motif (REM) and a GEF domain
characteristic for GEFs for Ras-like small
GTPases, and a cNMP domain, which,
however, does not bind cAMP with a
physiologically relevant affinity (151). It is
unknown which signal activates PDZ-GEFs, but
they have specific exchange activity towards
Rap1 and Rap2.
The family of Ras guanine nucleotide
releasing proteins (RasGRPs) (or CalDAG-
GEFs, for calcium- and diacylglycerol-regulated
GEFs) consists of four members which contain
putative calcium and DAG binding domains and
may be regulated by these second messengers.
RasGRP2 (CalDAG-GEFI) has exchange
activity towards Ras, RasGRP1 (CalDAG-
GEFII) towards Rap1 and Ras, RasGRP3
(CalDAG-GEFIII) towards Rap, Ras, and R-
Ras, and RasGRP4 (CalDAG-GEFIV) towards
Ras (90,152-155).
Due to a conserved glutamine residue at
position 61, Rap1 has very low intrinsic GTPase
activity, and therefore downregulation of Rap1
critically depends on the activity of  a number
of RapGAPs. The first RapGAP to be identified
was Rap1GAPI, and a longer transcript from the
same gene was called Rap1GAPII (156,157).
Their activity may be modulated by Gαi, Gαo,
and Gα z  subunits of large G proteins
(156,158,159). Furthermore, members of the
Spa family (Spa1, SPAR, SPAL, and E6TP1)
also stimulate GTPase activity of Rap1,
although it is largely unknown how their
activity is regulated (160-163). Recently it has
been suggested that Spa1 and Rap1GAPs may
be regulated by the scaffolding protein AF-6,
which simultaneously recruits Spa1/RapGAP
and Rap1 through its PDZ domain and its RBD,
respectively (164).  The subsequent
downregulation of Rap1 would thereby inhibit
adhesion of cells to fibronectin.
Cross-talk
Cross-talk between the cAMP-pathways
Cells may deploy extensive cross-talk
between cAMP signalling pathways. PKA can
directly phosphorylate Rap1 (165-176) and
Rap1GAP (177), although the consequences are
uncertain. In thyroid cells, upon cAMP
treatment, Epac activates a PI3K-PKB pathway,
whereas PKA simultaneously inhibits PKB
(80). Furthermore, PKA inhibits AC5 and AC6,
whereas it stimulates PDE3 and PDE4 activity,
all of which affect the availability of cAMP.
Calcium may be a central player in crosstalk
between the cAMP signalling pathways.
Numerous studies report crosstalk between
cAMP and calcium signalling pathways in
diverse cell types, like endothelial cells and
cardiac muscle cells (178-182) (Fig. 5). PKA,
Epac, and CNG-channels all affect calcium
levels in the cell. For instance, PKA can raise
calcium levels by stimulating the IP3 receptor
(IP3R) calcium channels (183), upon which
RapGEFs might be activated (184). Epac-Rap1
may also influence calcium fluxes through the
ryanodine-sensitive calcium channels (RyR)
(78,79) or IP3R calcium channels (77) and
possibly the sarco/endoplasmic reticulum Ca++-
ATPase (185,186). Subsequently, elevated
calcium levels can affect cAMP levels
(178,179). For instance, adenylate cyclases are
either stimulated or inhibited in various ways by
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Figure 5. Crosstalk between cAMP pathways, directly or via the second messenger calcium.
See text for details.
calcium, and PDE1 activity is enhanced by
Ca++-CaM. Since both calcium and cAMP are
not freely diffusible in the cell (10,11,17-19),
crosstalk between the Epac, PKA, and CNG
channel signalling pathways is likely to depend
on expression and specific localization of the
involved proteins in microdomains in the cell;
investigation of crosstalk in living cells remains
a major challenge.
cAMP, PKA, and Rap1 in  regulation of
ERK
cAMP agonists can either stimulate or
inhibit the ERK-1/2 pathway. It has been
hypothesized that this mainly depends on which
Raf isoforms are expressed in the cells (187).
In cells expressing Raf1, the Erk pathway
would be inhibited by cAMP. In this model,
cAMP would lead to activation of the small
GTPase Rap1 through a pathway involving
PKA and Src. Subsequently, Rap1 would form
an inactive complex with Raf1, resulting in
inhibition of ERK (188,189). However,
activation of Src by PKA has recently been
debated (190), and a number of studies have
shown that activation of Rap1 is independent of
PKA (69,70,116). Furthermore, growth factor
activation of endogenous Rap1 does not
correlate with inhibition of the ERK pathway
(116), and activation of Rap1 with a cAMP
analogue that specifically targets Epac but not
PKA did not result in inhibition of ERK
(chapter 2). Therefore, inhibition of the ERK
pathway by cAMP is likely to be mediated by
PKA and does not involve Rap1. Indeed, PKA
phosphorylates Raf1 on multiple sites, resulting
in Raf1 inhibition (Fig. 6). PKA also directly
inhibits p21 activated kinase (PAK), which can
phosphorylate the activating S338 residue in
Raf1 (191).
Conversely, in cells expressing B-Raf, the
ERK pathway would be activated by cAMP.
This model also involves Rap1, because in
contrast to the Rap1-Raf1 complex, the Rap1-B-
Raf complex is active (114,192). Many reports
support this model (140,148,156,189,193-209).
However, recent studies indicate that
endogenous Rap1 may not be involved in
cAMP-induced ERK activation, but rather point
towards a role for PKA and possibly Ras
((116,210-216); chapter 2). Which Ras-GEF
would mediate the cAMP signal, and whether
The small GTPase Rap1 in cAMP signalling
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Figure 6. Raf1 is activated by mitogens and inhibited by cAMP-PKA. Mitogen stimulation results in
phosphorylation of residues S338 (218) and Y341 (219), which synergize to stimulate kinase activity, and of T491,
S494 (220), and possibly S621 (221), all of which may modulate kinase activity (222). The inhibitory residue S259
and possibly S233 are phosphorylated in resting state, and are hyperphosphorylated upon cAMP treatment (223-
225). Dephosphorylation, possibly by PP2A (226), is essential for Raf1 activity. Phosphorylation of S259 interferes
with multiple steps of Raf1 function, including membrane recruitment, Ras binding, phosphorylation by activating
kinases, and coupling to substrates (225). Phosphorylation of S43 diminishes Ras binding (227), thereby inhibiting
ERK signalling, but its physiological relevance is still a matter of debate (224,228). The same holds true for
phosphorylation of S621, which has been claimed to be either activating or inhibiting (221).
Ras is not only required but actually also
sufficient for ERK activation remains elusive.
In addition, 14-3-3 proteins may also be
involved in cAMP-activation of ERK by
shielding B-Raf from inhibition by PKA (217).
In conclusion, direct regulation of the ERK
pathway by cAMP is likely to be independent of
Rap1.
Conclusions
cAMP regulates many cellular processes
through three different signalling pathways: the
PKA, Epac, and CNG-channel pathways. The
activity of each pathway may well be influenced
by the other pathways, depending on expression
and specific localization of the involved
proteins in microdomains in the cell. cAMP
activates Rap1 through Epac independently of
PKA. Whereas PKA is absolutely required for
regulation of the ERK pathway, Rap1 is clearly
not. Rather, Rap1 is involved in cAMP-induced
cell adhesion through modulation of integrin
activity. Furthermore, cAMP may regulate a
number of other processes through Epac and
Rap GTPases as well, like calcium release,
hormone secretion, and activation of p70S6K. It
remains a major challenge to identify the Rap
effector proteins which mediate these cAMP-
induced, Epac-mediated cellular processes.
Scope of this thesis
We studied the role of the Epac-Rap
pathway in cAMP signalling.
First, we developed an Epac-specific
cAMP analogue, which only targets the Epac
pathway and not the PKA pathway (chapter 2).
We used this analogue to investigate the role of
Rap1 in cAMP-regulation of ERK.
Next, we describe a novel function of
cAMP: cell adhesion (chapter 3). We show that
cAMP-induced cell adhesion is mediated by the
Epac-Rap1 pathway, and is independent of
PKA.
In chapter 4 we describe a function of the
Epac pathway in cAMP-induced activation of
p70S6K and its target ribosomal S6, which is
likely to be independent of PKA.
Finally, the possible consequences of these
findings are discussed in chapter 5.
Chapter 1; General introduction
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cAMP (1) is involved in a wide variety of cellular processes that were thought to be
mediated by protein kinase A (PKA). However, cAMP directly regulates Epac1 and
Epac2, guanine nucleotide exchange factors for the small GTPases Rap1 and Rap2
(2,3). Unfortunately, there is an absence of tools to discriminate between PKA- and
Epac-mediated effects. Therefore, through rational drug design we have developed a
novel cAMP analogue, 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3',5'-cyclic
monophosphate (8CPT-2Me-cAMP), which activates Epac, but not PKA both in
vitro and in vivo. Using this analogue, we tested the widespread model that Rap1
mediates cAMP-induced regulation of the extracellular signal-regulated kinase
(ERK) (4,5). However, both in cell lines in which cAMP inhibits growth factor-
induced ERK activation and in which cAMP activates ERK, 8CPT-2Me-cAMP did
not affect ERK activity. Moreover, in cell lines in which cAMP activates ERK,
inhibition of PKA and Ras, but not Rap1, abolished cAMP-mediated ERK
activation. We conclude that cAMP-induced regulation of ERK and activation of
Rap1 are independent processes.
Rap1 and Rap2 are the closest known
relatives of Ras. Interestingly, Rap1 was
identified in a genome-wide screen for
suppressors of Ras-transformation (6),
suggesting that Rap1 may antagonize Ras-
mediated signalling. This idea was supported by
experiments showing that the introduction of
constitutively active Rap1 results in the
downregulation of growth-factor-induced ERK
activation or subsequent ERK-mediated effects
(7,8). Additionally, activated Rap1 can form an
inactive complex with Raf1 (9,10), which led to
a model in which Rap1 interferes with Ras-
mediated ERK activation by trapping Raf1 in an
inactive complex. For instance, in cell lines
where cAMP inhibits Ras-mediated ERK
signalling (11), it was reported that Rap1
mediates this effect (4). Conversely, in cell lines
where cAMP activates rather than inhibits ERK,
Rap1 has also been implicated in the activation
of ERK (5). In this model, cAMP activates
Rap1, which would then interact with B-Raf, a
close relative of Raf1. In contrast to the Rap1-
Raf1 complex, the Rap1-B-raf complex is active
and promotes ERK activation (5,12). One
unresolved issue concerning the interactions
between cAMP, Rap1 and ERK is the role of
PKA. Although PKA is clearly required for
cAMP-induced activation of ERK, cAMP-
induced Rap1 activation through Epac is clearly
independent of PKA (2,3). This indicates that
cAMP-mediated regulation of ERK and Rap1
are independent processes, and therefore the
role of Rap1 in cAMP-induced ERK activation
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is questionable. Indeed, a number of groups
have reported alternative mechanisms for
cAMP-induced regulation of ERK that occur
independently of Rap1 (13-20).
To determine whether ERK is regulated by
the cAMP-PKA pathway or the cAMP-Epac-
Rap1 pathway we generated a novel cAMP
analogue that can activate Epac, but not PKA.
First, we compared the amino-acid sequences of
the Epac cAMP binding domains with all other
known cyclic-nucleotide-binding domains,
including the cAMP domains of PKA, olfactory
and pacemaker channels and the bacterial
catabolite gene activator protein. We noticed
that the highly conserved glutamate that forms
hydrogen bonds with the 2'-hydroxyl of the
ribose group of cAMP (21) was absent in the
cAMP binding domain of Epac1 and in the
high-affinity cAMP-binding-domain B of Epac2
(Fig. 1a). We hypothesized that this 2'-hydroxyl
group, which is absolutely required for high-
affinity binding of cAMP to the cAMP-binding
domain of PKA, might not be required for
efficient binding to and activation of Epac. On
the basis of this assumption, we synthesized
(synthesis method modified after (22)) and
tested a large number of compounds, one of
which, 8CPT-2Me-cAMP, was a very efficient
activator of Epac1 in vitro (Fig. 1b). Half-
maximal activation of Epac1 was observed at
2.2 µM 8CPT-2Me-cAMP, compared with 30
µM for cAMP (Fig. 1c). Interestingly, binding
of 8CPT-2Me-cAMP to Epac1 results in a
threefold higher maximal activity than that of
cAMP, demonstrating that 8CPT-2Me-cAMP is
a more potent allosteric regulator of Epac1 than
cAMP. Currently, it is unclear why 8CPT-2Me-
cAMP activates Epac more efficiently in vitro
than cAMP, even at saturating conditions. This
will be the subject of further investigations. In
contrast, the ability of 8CPT-2Me-cAMP to
activate the type-I and type-II holoenzymes of
PKA was greatly impaired when compared with
cAMP (Fig. 1d). These in vitro results indicate
that 8CPT-2Me-cAMP may also function as a
very potent compound to discriminate between
the Epac and the PKA signalling pathways in
vivo. Therefore, the effect of 8CPT-2Me-cAMP
treatment was tested in NIH3T3-A14-Epac1
cells. We used Rap1 activity as an indicator of
Epac activation, and phosphorylation of the
common PKA substrate CREB (cAMP-
responsive element binding protein) (23) as an
indicator for PKA activition. Importantly,
whereas 8-Br-cAMP induced both the activation
of Rap1 and the phosphorylation of CREB (Fig.
1e, top), 8CPT-2Me-cAMP induced the
activation of Rap1 only. Serial dilution
experiments demonstrated that  10 µM 8CPT-
2Me-cAMP already activates Rap1 (Fig. 1e,
middle). However, 8CPT-2Me-cAMP did not
induce phosphorylation of CREB, even at 100
µM (Fig. 1e, bottom). Taken together, we
conclude that 8CPT-2Me-cAMP is a highly
specific and efficient activator of Rap1, as well
as a very useful tool to discriminate between the
PKA- and Epac-Rap-mediated signalling
pathways. Although we have not tested the
effect of 8CPT-2Me-cAMP on olfactory and
pacemaker channels, we predict that these
proteins will not be affected, as both channels
also contain the conserved glutamate in their
cAMP-binding domains. One of the proposed
functions of Rap1 is to antagonize Ras-
mediated activation of ERK, by binding to and
inhibiting Raf1 (7,8,10). We tested this model
using 8CPT-2Me-cAMP in NIH-3T3-A14 cells
stably expressing Epac1, which should boost the
activation of endogenous Rap1. In these cells,
8-Br-cAMP efficiently activated Rap1 (Fig. 1e)
and inhibits insulin-induced activation of ERK
(Fig. 2a, top). This cAMP-induced inactivation
of ERK is rescued by the PKA inhibitor, H-89,
confirming previous results that PKA mediates
this effect. Although 8CPT-2Me-cAMP
efficiently activates Rap1 in these cells (Fig.
1e), no effect on insulin-induced ERK
activation was detected, even at concentrations
of 1 mM (Fig. 2b). Although these high
concentrations of 8CPT-2Me-cAMP can
activate PKA in vitro, it is apparently not
sufficient for activation in vivo. The reason for
this discrepancy is unclear, but it is has been
generally observed that activation of PKA in
vivo requires much higher concentrations of
cAMP analogues than is required in vitro
(S.O.D., unpublished observations and review
manuscript in preparation). In contrast with
8CPT-2Me-cAMP, 8-Br-cAMP efficiently
inhibited ERK activation at a concentration of
300 µM. These results show that cAMP-
induced activation of Rap1 is not sufficient to
inhibit growth-factor-induced activation of
ERK.
In cell lines in which cAMP activates
ERK, Rap1 has been proposed to mediate this
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Figure 1. Identification of an Epac-specific cAMP analogue. a, Alignment of the cAMP binding domains of PKA,
Epac, olfactory channels, pacemaker channels and the bacterial CAP protein. b, In vitro activation of Epac1. The left
panel shows Rap1 loaded with fluorescent Mant-GDP in the presence of 100-fold excess of GTP and incubated with
or without Epac1-∆DEP in the presence of increasing concentrations of cAMP. The right panel shows Rap1 loaded
with fluorescent Mant-GDP in the presence of 100-fold excess of GTP and incubated with or without Epac1-∆DEP in
the presence of increasing concentrations of 8CPT-2Me-cAMP, as indicated. c, The in vitro reaction rates of Epac for
cAMP and 8CPT-2Me-cAMP. d, In vitro PKA activity of either type-I holoenzyme (top) or type-II holoenzyme (bottom)
at increasing concentrations of cAMP or 8CPT-2Me-cAMP. e, 8CPT-2Me-cAMP activates Rap1, but not PKA, in vivo.
NIH3T3-A14-Epac1 cells were treated with 8-Br-cAMP for 15 min (top). Cells were lysed and assayed for GTP-
bound Rap1. Phosphorylation of CREB in corresponding cell lysates was analysed using a phospho-specific CREB
antibody. NIH3T3-A14-Epac1 cells were treated in duplicate for 15 min with increasing concentrations of 8CPT-2Me-
cAMP. Cell lysates were then analysed for activation of Rap1 (middle) and phosphorylation of CREB (bottom).
effect by binding to and activating B-Raf. To
determine whether Rap1 is indeed involved in
cAMP-dependent activation of ERK, we
incubated Chinese hamster ovary (CHO) cells
with either 8-Br-cAMP or 8CPT-2Me-cAMP.
Although both analogues efficiently activated
Rap1, only 8-Br-cAMP activated ERK and
induced phosphorylation of CREB (Fig. 3a).
Similar responses were also detected in Ovcar3
cells treated with 8-Br-cAMP or 8CPT-2Me-
cAMP (Fig. 3b). Furthermore, 8-Br-cAMP, but
not 8CPT-2Me-cAMP, activated ERK in PC12
cells and HEK293T cells (Fig. 3c), whereas
Rap1 was readily activated by 8CPT-2Me-
cAMP (Fig. 3d). Taken together, we conclude
that cAMP-induced activation of Rap1 is not
sufficient to activate ERK.
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Figure 2. ERK is inhibited by 8-Br-cAMP, but not by
8CPT-2Me-cAMP. a, 8CPT-2Me-cAMP does not block
insulin-induced ERK activation (top). NIH3T3-A14-
Epac1 cells were either pretreated or not pretreated with
the PKA inhibitor H-89 for 30 min, before treatment with
8-Br-cAMP or 8CPT-2Me-cAMP (100 µM) for 15 min.
Subsequently, cells were stimulated with insulin for 5
min. Cells were lysed and phosphorylation of ERK was
assayed by mobility shift through western blotting with
an ERK1/2 antibody. As a control for PKA activation,
CREB phosphorylation was analysed using a phospho-
CREB antibody (middle). As a control for 8CPT-2Me-
cAMP, cells were pretreated with 100 µM 8CPT-2Me-
cAMP for 15 min before insulin treatment for 5 min
(bottom). Cells were assayed for GTP-bound Rap1. b,
8CPT-2Me-cAMP does not block activation of ERK at
high concentrations. Where indicated, cells were
pretreated with H-89 for 30 min before treatment with
increasing concentrations of 8CPT-2Me-cAMP or 8-Br-
cAMP for 15 min. Subsequently, cells were stimulated
with insulin for 5 min. Cells were lysed and ERK
phosphorylation was assayed by mobility shift through
western blotting with an ERK1/2 antibody.
Next, we investigated whether activation
of Rap1 is still required for cAMP-induced
activation of ERK in cell lines in which cAMP
activates ERK. For these experiments, we used
CHO-β2M3 cells, which express the β 2
adrenergic receptor (β2-AR) and the M3
muscarinic receptor (M3-MR), thus providing a
system with a physiological set-up that can be
induced by extracellular stimuli. Stimulation of
β2-AR with isoproterenol activates ERK
through the Gs heterotrimeric G-protein subunit,
whereas stimulation of the M3-MR with
carbachol results in cAMP-independent ERK
activation through the Gq G-protein subunit. In
these cells, isoproterenol activated ERK and
Rap1 (Fig. 4a). Ras is induced by isoproterenol,
alhough the effect is weak (Fig. 4a).
Isoproterenol-, forskolin-, or 8-Br-cAMP-
induced activation of ERK is sensitive to H-89,
whereas Rap1 activation is insensitive to H-89
(Fig. 4b and data not shown). As a control,
carbachol-induced activation of ERK was
insensitive to H-89 (Fig. 4b). Furthermore, in all
other cell lines tested, cAMP-dependent
activation of Rap1 was insensitive to H-89 and
Rap1 was readily activated by 8CPT-2Me-
cAMP ((3) and J.M.E., J.d.R. and J.L.B.,
unpublished observations). Furthermore,
activation of ERK with isoproterenol and
carbachol was sensitive to the MEK inhibitors,
PD98059 and U0126, demonstrating that
activation of ERK is MEK-dependent (Fig. 4b).
Thus, in these cells, cAMP-induced ERK
activation, but not Rap1 activation, is mediated
by PKA. We next isolated clonal CHO-β2M3
cell lines that stably express haemagglutinin
(HA)-tagged Rap1GAP1, a GTPase activating
protein for Rap1. In these cell lines, Rap1 could
no longer be activated by isoproterenol,
forskolin or 8-Br-cAMP, whereas ERK
activation was unaffected (Fig. 4c and not
shown). Furthermore, isoproterenol and
forskolin induced ERK activation with normal
kinetics (Fig. 4d). From these results, we
conclude that Rap1 is not involved in cAMP-
induced ERK activation. The cAMP analogue
8CPT-2Me-cAMP is an important tool for
deciphering the functions of cAMP, as almost
all commercially available cAMP analogues we
have tested regulate both PKA and Epac (A.E.C
and J.d.R, manuscript in preparation). 8CPT-
2Me-cAMP will allow us to measure the effects
of activating the Epac-Rap1 pathway in a more
physiological setting, that is, activation of
endogenous Epac, Rap1 and Rap2. We have
used 8CPT-2Me-cAMP to investigate the
proposed role of Rap1 in cAMP-mediated
regulation of ERK. Importantly, 8CPT-2Me-
cAMP did not affect the regulation of ERK in a
number of cell lines in which 8-Br-cAMP either
induced ERK activation or inhibited growth-
factor-induced activation of ERK. This result
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Figure 3. cAMP-induced activation of ERK and Rap1 are distinct processes. a, ERK is activated by 8-Br-cAMP,
but not by 8CPT-2Me-cAMP, in CHO cells. Cells were treated with either 8-Br-cAMP or 100 µM 8CPT-2Me-cAMP for
15 min. Cells were lysed and assayed for GTP-bound Rap1. ERK phosphorylation was assayed by mobility shift
through western blotting with an ERK1/2 antibody. CREB phosphorylation was assayed by western blotting with a
phospho-CREB antibody. b, ERK is activated by 8-Br-cAMP, but not by 8CPT-2Me-cAMP, in Ovcar3 cells. Cells
were treated with 8-Br-cAMP or 8CPT-2Me-cAMP (30 µM) for the indicated times. Equal amounts of cell lysate were
assayed for GTP-bound Rap1. Phosphorylation of ERK and CREB was assayed using phospho-specific ERK and
CREB antibodies. c, ERK is activated by 8-Br-cAMP, but not by 8CPT-2Me-cAMP, in PC12 and HEK293T cells.
PC12 cells (top) or HEK293T cells (bottom) were treated with 30 µM 8CPT-2MecAMP or 8-Br-cAMP for the indicated
times, or with TPA for 10 min. Equal amounts of cells lysate were analysed for ERK phosphorylation by western
blotting with a phospho-specific ERK antibody. d, As a control, 8CPT-2Me-cAMP readily activates Rap1. PC12 cells
were treated in duplicate for 15 min with 8CPT-2Me-cAMP or 8-BrcAMP. Equal amounts of cell lysates were
analysed for activation of Rap1 (top) and phosphorylation of ERK (bottom).
was unsurprising, considering the widely
accepted role of PKA in cAMP-mediated
regulation of ERK. Furthermore, our studies
with Rap1GAP1-overexpressing cells clearly
show that Rap1 activity is completely
dispensable for activation of ERK. These results
are clearly at odds with a prominent role for
Rap1 in the regulation of ERK (4,5). This role
originates from the early finding that Rap1
suppresses Ras-mediated transformation and
also from the high similarity between Ras and
Rap1, particularly in the effector domain.
Indeed, Rap1 has also been shown to interact
with Ras effectors, such as Raf1, B-Raf and
RalGEFs both in vitro and in overexpression
systems (9,24). However, several studies have
already indicated that Rap1 may not be involved
in modulating ERK activity (24,25). For
instance, activation of endogenous Rap1 by
endothelin did not affect ERK activity and
expression of activated Rap1 under the control
of a T-cell specific promoter in mice did not
affect ERK activity in the subsequently isolated
T-cells (26). Furthermore, in genetic screens of
lower eukaryotes, no elements of the Rap1
signalling pathway were found to affect the
Ras-ERK pathway (27). Of course, indirect
regulation of ERK by Rap1 is still possible. For
instance, Rap1 has been shown to regulate
integrin-mediated cell adhesion (28), an effect
that can be mimicked by 8CPT-2Me-cAMP
(29). Indeed, activation of integrins results in
‘outside-in’ signalling that also affects ERK
activity. Previously, it has been reported that the
activation of Rap1 is mediated by PKA (5). Our
results do not formally exclude the possibility
that two pathways exist to activate Rap1 -one
mediated by PKA and one mediated by Epac- of
which only the PKA-mediated Rap1 pathway
may be involved in the activation of ERK.
However, cAMP-induced activation of ERK is
not abolished in the Rap1GAP1-overexpressing
cell lines, an observation that is at odds with
this model. Furthermore, PKA-induced
phosphorylation of Rap1 at Ser179 has been
suggested to be involved in the activation
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Figure 4. cAMP-induced ERK activation is mediated by PKA and Ras. a, Isoproterenol activates ERK, Rap1 and
Ras in CHO-β2M3 cells. Cells were treated with isoproterenol for the indicated times and assayed for GTP-bound
Rap1 and GTP-bound Ras. Activation of ERK was analysed by western blotting with a phosphospecific ERK
antibody. b, Isoproterenol-induced activation of ERK, but not Rap1, is blocked by inhibitors of PKA and MEK. CHO
cells were pretreated for 30 min with H-89 or the MEK inhibitors, PD98059 or U0126. Cells were then treated with
isoproterenol or carbachol for 5 min. Cell lysates were assayed for ERK2 phosphorylation by mobility shift, detected
by western blotting (top) and Rap1 activation (bottom). c, Expression of Rap1-GAP1 blocks isoproterenol-induced
activation of Rap1, but not ERK. Four HA-tagged Rap1-GAP1-expressing clonal CHO-β2M3 cell lines (Rap1-
GAP1.1–1.4) and a mock-transfected clonal cell line were treated with isoproterenol for 5 min. Cell lysates were
assayed for Rap1 activation and ERK phosphorylation. Expression of Rap1-GAP1 was confirmed by western blotting
with anti-HA antibodies. d, Kinetics of ERK activation are identical in untransfected cells (top), mock-transfected cells
(middle) and Rap1-GAP1-expressing cells (bottom). Cells were treated with isoproterenol for the indicated times and
the kinetics of ERK2 phosphorylation were assayed by mobility shift. Similar results were obtained in three additional
Rap1-GAP1-expressing cell lines (data not shown). e, Dominant negative RasS17N blocks forskolin-induced ERK
activation. Mock-transfected cells and RasS17N-expressing cells (top) were pretreated with H-89 (30 min), forskolin (10
min) or carbachol (5 min), as indicated. ERK2 phosphorylation was assayed by mobility shift. Mock-transfected CHO-
β2M3 cells and RasS17N-expressing cells were treated with forskolin (10 min), isoproterenol (5 min) or carbachol (5
min), as indicated. Cell lysates were assayed for Rap1 activation. Expression of RasS17N was detected by western
blotting with anti-HA antibodies.
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of Rap1 (5), although the precise function of
this phosphorylation is still unclear.
If Rap1 is not involved in the regulation of
ERK activity, what are the alternative
mechanisms? For cAMP-induced inhibition of
growth-factor-induced ERK activation, direct
phosphorylation of Raf1 is the most attractive
alternative. Recently two studies showed that
Raf1 is phosphorylated by PKA and thereby
inactivated. (16,17). Our results suggest that
Ras is involved in the activation of ERK by
cAMP, although how PKA activates Ras is
unclear. Alternatively, as activation of Ras by
cAMP is generally weak, Ras may cooperate
with a target of PKA to induce ERK activity.
Several additional possibilities have been
described, such as the regulation of an ERK
phosphatase (18) and PKA-independent
regulation of Ras in melanocytes (19). Studies
of these alternative pathways provide further
support for our observations that cAMP-induced
activation of Rap1 and cAMP-mediated
regulation of ERK are independent processes.
Methods
Reagents
Antibodies against the following proteins were used:
polyclonal phospho-p44/42 MAP Kinase (Thr202/Tyr204)
and polyclonal phospho-CREB (Ser133) (Cell Signalling,
Beverly, MA, USA), Ras (Transduction Laboratories,
Lexington, NY, USA), Rap1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The following inhibitors and stimuli
were used at concentrations indicated, unless stated
otherwise: H-89 (10 µM), PD98059 (50 µM) and U0126 (25
µM) (Biomol Research Laboratories Inc., Plymouth Meeting,
PA, USA). Insulin (1 µg/ml), TPA (100 ng/ml), isoproterenol
(10 µM) and carbamylcholine (carbachol, 100 µM) (Sigma-
Aldrich, Steinheim, Germany). Forskolin (25 µM) (ICN,
Costa Mesa, CA, USA), 8-Br-cAMP (1 mM) (Biolog Life
Science Institute, Bremen, Germany).
Cells, plasmids, transfections
CHO cells stably expressing the β2-adrenergic and the M3-
muscarinic receptor were maintained in αMEM with 10%
foetal calf serum and 0.25 mg/ml hygromycin-B (Roche
Diagnostics, Mannheim, Germany). Clonal cell lines were
generated by calcium phosphate cotransfection of pBABE
with either pMT2HA, pMT2HA-H-RasS17N, pMT2HA-
Rap1GAP1 (28) and selection with puromycin 15 µg/ml.
NIH3T3-A14 cells stably expressing Epac1 were grown in
DMEM with 10% foetal calf serum and 2 µg/ml puromycin,
Ovcar3 cells were maintained in RPMI with 10% foetal calf
serum, HEK293T cells were maintained in DMEM with 10%
foetal calf serum, PC12 cells in RPMI with 5% foetal calf
serum and 10% donor horse serum. All cells except CHO
cells were serum starved 16 hours prior to stimulation.
In vitro analyses
Cyclic AMP dependent protein kinase I and II were
reconstituted from isolated subunits and assayed for kinase
activity using 70 mM kemptide as substrate as described
previously (30). Epac activation was measured as described
(3) using 600 nM Rap1b loaded with the fluorescent
nucleotide mantGDP in the presence of 100-fold excess GTP
and in the absence or presence of 150 nM Epac1∆DEP1.
Increasing concentrations of cAMP or 8CPT-2Me-cAMP
were added and single exponential curves were fit to the data
to calculate reaction rates. Reactions were carried out in 96-
well plates and measured in a Cary Eclipse from Varian Inc.
using the manufacturers software.
In vivo analyses
Ras and Rap activation assays were performed as described
previously (31). Phosphorylation of ERKs was either
analysed by mobility shift on SDS-PAGE, which
accompanies phosphorylation of these proteins, or western
blotting using the phospho-specific antibody against ERK,
where indicated.
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Cyclic AMP (cAMP) controls many cellular processes mainly through the activation
of protein kinase A (PKA). However, more recently PKA-independent pathways
have been established through the exchange protein directly activated by cAMP
(Epac), a guanine nucleotide exchange factor for the small GTPases Rap1 and Rap2.
In this report, we show that cAMP can induce integrin-mediated cell adhesion
through Epac and Rap1. Indeed, when Ovcar3 cells were treated with cAMP, cells
adhered more rapidly to fibronectin. This cAMP effect was insensitive to the PKA
inhibitor H-89. A similar increase was observed when the cells were transfected with
Epac. Both the cAMP effect and the Epac effect on cell adhesion were abolished by
the expression of Rap1-GTPase activating protein, indicating the involvement of
Rap1 in the signalling pathway. Importantly, a recently characterized cAMP
analog, 8-(4-Chloro-phenylthio)-2’-O-methyladenosine-3’,5’-cyclic monophosphate,
which specifically activates Epac but not PKA, induced Rap-dependent cell
adhesion. Finally, we demonstrate that external stimuli of cAMP signalling, i.e.
isoproterenol, which activates the Gαs-coupled β2-adrenergic receptor can induce
integrin-mediated cell adhesion through the Epac-Rap1 pathway. From these results
we conclude that cAMP mediates receptor-induced integrin-mediated cell adhesion
to fibronectin through the Epac-Rap1 signalling pathway.
cAMP is a common second messenger
controlling many cellular processes. PKA is a
general receptor for cAMP, resulting in the
phosphorylation of a large variety of cellular
targets. Specificity is regulated by AKAP
proteins that target PKA to specific regions in
the cell. A few years ago we discovered an
additional cAMP target, Epac1 (exchange
protein directly activated by cAMP). This
protein, and its close relative Epac2 contain
cAMP-binding domains very similar to the
cAMP binding domains in the regulatory
subunit of PKA, and are exchange factors for
the small GTPases Rap1 and Rap2 (1-3).
Rap1 is a GTPase of the Ras superfamily,
which functions as a molecular “switch”,
cycling between inactive GDP- and active GTP-
bound forms. Specific guanine nucleotide
exchange factors are the “on switches” and
GTPase-activating proteins (GAPs) are the “off
switches” (for review see (4)). Rap1 was
initially identified in a screen for proteins that
can suppress the transformed phenotype of
fibroblasts transformed by oncogenic K-Ras (5),
providing a model in which Rap1 functions as
an antagonist of Ras signalling mainly by
trapping Ras effectors (Raf1) in an inactive
complex. However, from numerous reports
accumulated so far, it is evident that Rap1
signalling is important in itself, and
independently of Ras regulates several
important cellular processes (4). One of the
most consistent findings is the involvement of
Rap1 in integrin-mediated cell adhesion (6-12).
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Integrins are heterodimeric cell adhesion
molecules consisting of one of several different
α  chains and one of at least five different β
chains. One of the first indications was that in
32D cells granulocyte colony stimulating factor-
induced cell adhesion could be abolished by the
introduction of Spa1, a GAP for Rap proteins
(13). This finding was followed by three
independent observations showing a role for
Rap1 in the inside-out signalling to integrins.
First, in Jurkat cells introduction of Rap1
induced integrin αL β2 (LFA1)-mediated
adhesion to the intercellular adhesion molecule.
Importantly, adhesion induced by ligation of the
T-cell receptor was inhibited by introduction of
an interfering mutant of Rap1 (8). Second, also
in Jurkat cells ligation of the adhesion molecule
CD-31 induced activation of αLβ2, which was
inhibited by blocking Rap1 signalling (9).
Finally, in a macrophage cell line, complement-
mediated phagocytosis, which requires activated
αMβ2, was abolished by inhibition of Rap1
signalling (6). Other studies reached the same
conclusion for integrins with a β1 chain, i.e.
α5β1 (7) and for integrins with a β3 chain, i.e.
αIIbβ3 (14). Recently, it was shown that in
mice expressing active Rap1 in their T-cell
compartment both the thymocytes and mature T
cells exhibited increased integrin-mediated cell
adhesion. In addition, these cells showed
enhanced T cell receptor-mediated responses
(12). From the above results we hypothesized
that cAMP or signals that raise cAMP levels
may regulate integrin-mediated cell adhesion
through Epac and Rap1. We have tested this
model and found that indeed cAMP was able to
induce integrin-mediated cell adhesion to
fibronectin. It has been reported previously that
PKA was a key part in a signalling pathway
activated by mAb 12G10, an antibody that can
activate β1 integrins and induce integrin-
mediated cell-cell and cell-substrate adhesion in
human fibrosarcoma cells (15). To distinguish
which of the two independent cAMP signalling
pathways, mediated by either PKA or Epac, is
involved in integrin regulation in Ovcar3 cells,
we used a novel analogue of cAMP, 8-(4-
Chloro-phenylthio)-2’-O-methyladenosine-
3’,5’-cyclic monophosphate (8CPT-2Me-
cAMP) that specifically targets Epac and not
PKA. We demonstrate that an Epac-Rap1
pathway mediates this effect independently of
PKA. We also implicate physiological
consequences of intracellular increases in
cAMP in vivo by demonstrating that agonist
stimulation of the β2-adrenergic receptor is
linked to increased cell adhesion via Rap1.
Results and discussion
To investigate whether cAMP could induce
integrin-mediated cell adhesion, we used
ovarian carcinoma cells (Ovcar3), since these
cells express the β1 integrin chain in association
with α  chains 1-6 and αv, with the α5β1 and
αvβ3  integrins mediating binding to fibronectin
(16,17). Cytomegalovirus-luciferase-transfected
cells were detached with trypsin and allowed to
reexpress cell surface markers. The cells were
seeded onto fibronectin-coated multi-well plates
in the presence or absence of 8-Br-cAMP, and
the amount of cells that adhered after a certain
period of time was quantified. We observed that
8-Br-cAMP augmented cell adhesion and
activated Rap1 in a concentration-dependent
manner to fibronectin (EC50 ~ 0.2-0.5 mM)
(Fig. 1 a and b). Rap1 was activated rapidly and
remained active for at least 3 h. 8-Br-cAMP-
induced adhesion was also observed using a
different promoter (thymidine kinase [TK]-
luciferase) driving luciferase expression, and a
direct method of measuring adhesion by
counting cells (unpublished data). Cell adhesion
induced by cAMP was insensitive to the PKA
inhibitor H-89 when cells were pretreated for a
short time just before adhesion (Fig. 1c, Short).
It has been reported that detachment of cells
rapidly and transiently activates PKA, one of
the well-established targets of cAMP (18),
raising the possibility that if a potential PKA
substrate with a sustained phosphorylation
profile was involved, addition of H-89 at a later
time (post-PKA activation) may falsely imply a
PKA-independent mechanism. However, when
cells were treated with H-89 before
trypsinization and throughout the recovery
period, we found that cAMP-induced adhesion
was not blocked (Fig. 1c, Long), indicating that
indeed PKA was not involved. As a control for
H-89 activity we measured cAMP-induced
phosphorylation of the direct PKA target CREB
(19) and ERK, which is also PKA-dependent
(Fig. 1d). Activation of Rap1, which is
independent of PKA (1,3,20) was measured
also. From these results we conclude that
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Figure 1. cAMP induces
c e l l  a d h e s i o n  t o
fibronectin in a PKA-
independent manner. a,
Treatment with 8-Br-cAMP
induces adhesion to
fibronectin. Ovcar3 cells
were transiently transfected
w i th  CMV- luc i f e rase
plasmid, and cells adhering
to fibronectin (2 µg/ml) in
the presence of increasing
concentrations of 8-Br-
cAMP were quantified as
described in Materials and
methods. b , 8-Br-cAMP
induces Rap1 activation.
(Top) Ovcar3 cells were
treated with increasing
concentrations 8-Br-cAMP
for 15 min. Cells were lysed,
and equal amounts of cell
lysate were analyzed for
activation of Rap1 (top blot)
and CREB (bottom blot).
Total levels of Rap1 in cell
lysates are shown (middle
blot). (Bottom) Ovcar3 cells
were treated with 1 mM 8-Br-cAMP for the indicated times. Cells were lysed as above and analyzed for activation of
Rap1 (top blot) and CREB (bottom blot). Total Rap1 levels are shown (middle blot). c, 8-Br-cAMP–induced adhesion
is independent of PKA. Ovcar3 cells transiently transfected with CMV-luciferase plasmid were either preincubated at
370C for 30 min with the PKA inhibitor H-89 (10 µM) 30 min before seeding onto the wells (Short), or H-89 was added
30 min before trypsinization and during the recovery period (Long) and seeded onto wells with or without 8-Br-cAMP.
Cells were allowed to adhere for 1 h, and nonadherent cells were removed. The percentage of adherent cells was
quantified and plotted relative to unstimulated cells (range from 2–10%). The plot shown is representative of two
(long pretreatment) and five (short pretreatment) experiments each in triplicate. Error bars represent SD. d,
Activation of CREB and ERK but not Rap1 is blocked by H-89. Ovcar3 cells were pretreated with either H-89 or
carrier for 30 min followed by stimulation with 8-Br-cAMP for 15 min. Cells were lysed, and equal amounts of cell
lysates were incubated with precoupled GST-RalGDS-RBD, and activation of Rap1 was analyzed by immunoblotting
using a Rap1 antibody. Phosphorylation of CREB and ERK was assayed by Western blotting using phospho-specific
antibodies.
in Ovcar3 cells cAMP can induce cell adhesion
to fibronectin independently of PKA.
Our finding that the induction of integrin-
mediated cell adhesion by cAMP is independent
of PKA suggested that Epac-Rap1 might be
mediating this effect. To further test this idea,
Ovcar3 cells were transiently transfected with
Epac1. This resulted in an increase in basal
adhesion to fibronectin, which was further
increased by stimulation with 8-Br-cAMP (Fig.
2a), suggesting that Epac mediates cAMP-
induced cell adhesion. This observation was
further strengthened by the introduction of
Rap1GAPII, an inhibitor of Rap1 (21), which
attenuated Epac-induced cell adhesion (Fig. 2a).
These results show that ectopic expression of
Epac is sufficient to induce Rap1-dependent cell
adhesion to fibronectin, which can be enhanced
by additional stimulation with cAMP. It should
be noted that although Rap1GAPII is more
effective on Rap1 than on Rap2, we cannot
exclude a role for Rap2 in this process.
To formally exclude the possibility that
cAMP and Epac are on parallel pathways, both
of which would be required for the induction of
cell adhesion, we used a newly characterized
analogue of cAMP, 8CPT-2Me-cAMP, which
specifically activates Epac but not PKA even at
high concentrations (20). As observed with 8-
Br-cAMP, stimulation of Epac1-transfected
cells with 8CPT-2Me-cAMP further increased
cell adhesion to fibronectin (Fig. 2b),
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Figure 2. Overexpression of
Epac1 increases cAMP-
induced cell adhesion,
which is Rap1GAPII
sensitive. a, 8-Br-cAMP-
Epac1–induced cell adhesion
is blocked by Rap1GAPII.
Ovcar3 cells were transiently
transfected with TK-luciferase
plasmid and either mock
DNA (vector), HA-tagged
Epac1, or  HA-tagged
Rap1GAPII where indicated.
Cells were stimulated with 8-
Br-cAMP, and adhesion of
cells to fibronectin was
quantified. The percentage of
adherent cells was plotted
relative to unstimulated,
mock-transfected cel ls.
R e p r e s e n t a t i v e  d a t a
performed in triplicate are
shown, and error bars
r e p r e s e n t  S D .  T h e
experiments were repeated
at least four times with
identical results. b, 8CPT-
2Me-cAMP-Epac1–induced
cell adhesion is blocked by
Rap1GAPII. Ovcar3 cell were
transiently transfected as
above. Cells were stimulated
with 8CPT-2Me-cAMP, and
adhesion of cel ls to
fibronectin was quantified.
The percentage of adherent
cells was plotted relative to
u n s t i m u l a t e d ,  m o c k -
transfected cells. Representative data performed in triplicate are shown, and error bars represent SD. The
experiments were repeated at least four times with identical results. c, 8CPT-2Me-cAMP-Epac1–induced Rap1
activation is blocked by Rap1GAPII. Cells were treated with 50 µM 8CPT-2Me-cAMP for 15 min, lysed, and GTP-
bound Rap1 levels were determined as described in Materials and methods (top). Rap1 protein levels were equal
(middle), and expression of transfected proteins was confirmed with an anti-HA antibody (bottom). d, A β 1-
integrin–blocking peptide containing the RGD sequence present in fibronectin inhibits 8CPT-2Me-cAMP–induced cell
adhesion. Ovcar3 cells were pretreated for 20 min with RGD peptide (100 µM) where indicated and seeded in wells
with or without 8CPT-2Me-cAMP. Cells were allowed to adhere for 1 h, and nonadherent cells were removed. The
percentage of adherent cells was measured and plotted relative to unstimulated cells. Representative data from two
experiments performed in triplicate are shown with error bars representing SD. E, 8CPT-2Me-cAMP does not
increase the rate of cell adhesion to poly-L-lysine. Ovcar3 cells were transfected with CMV-luciferase and seeded
onto poly-L-lysine–coated plates. At various time points, nonadherentcells were removed and adherent cells were
quantified. A representative experiment in triplicate is shown.
and raised Rap1GTP levels (Fig. 2c).
Expression of Rap1GAPII inhibited adhesion of
cells to fibronectin and completely abolished
Rap1GTP levels (Fig. 2 b and c), indicating that
Rap1 is critically involved in cAMP-induced
cell adhesion. We next investigated whether
activation of endogenous Epac is sufficient to
induce adhesion to fibronectin. Ovcar3 cells
were treated with 8CPT-2Me-cAMP to activate
endogenous Epac, which is abundantly
expressed in ovary tissue (3). Indeed, 8CPT-
2Me-cAMP significantly induced cell adhesion
to fibronectin (Fig. 2d). To investigate whether
cAMP-induced cell adhesion is indeed mediated
by integrins, we pretreated Ovcar3 cells with
the β1-integrin-binding arginine, glycine,
aspartic acid (RGD) peptide. Peptides
containing the RGD amino acid sequence
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Figure 3. 8CPT-2Me-cAMP induces
cell adhesion via Epac and Rap1.
a, 8CPT-2Me-cAMP stimulates cell
adhesion. (Top) Ovcar3 cells were
transient ly t ransfected with
CMVluciferase plasmid and treated
with increasing concentrations of
8CPT-2MecAMP. Cells adhering to
fibronectin (2 µg/ml) were quantified
as described in Materials and
methods. (Bottom) Ovcar3 cells
were treated with increasing
concentrations of 8CPT-2Me-cAMP
for 15 min, and cells were lysed and
analyzed for activation of Rap1 (top
blot) and CREB (bottom blot). Total
Rap1 levels are shown (middle blot).
b, 8CPT-2MecAMP increases the
rate of cell adhesion. (Top) Ovcar3
cells were transfected with TK-
luciferase and seeded onto
fibronectin-coated plates. At various
time points, nonadherent cells were
removed, and adherent cells were
quantified. (Bottom) cells were
treated with 60 µM 8CPT- 2Me-
cAMP for the indicated times. Cells
were lysed, and equal amounts of
cell lysates were analyzed for
activation of Rap1 (top blot) and
CREB (bottom blot). Total levels of
Rap1 in cell lysates are shown
(middle blot). c, Ovcar3 cells were
pretreated with H-89 as described in
the legend to Fig. 1 C and seeded
onto wells in the absence or
presence of 8CPT-2Me-cAMP (100 µM). Cells were allowed to adhere for 1 h, and nonadherent cells were removed.
The percentage of adherent cells was quantified and plotted relative to unstimulated cells (range from 2–10%). The
plot shown is representative of two (long pretreatment) and five (short pretreatment) experiments, each in triplicate.
Error bars represent SD. d, cAMP-induced adhesion to fibronectin is blocked by inhibitors of Rap1. (Left) Ovcar3
cells were transiently transfected with CMV-luciferase and either mock DNA, increasing concentrations of HA-
Rap1GAP II (0.5, 1, 2, or 6 µg, respectively), HA-Rap1GAPI (6 µg), or HA-RBD of RalGDS (6 µg), respectively. Cells
were treated with 8-Br-cAMP or 8CPT-2Me-cAMP, and adhesion to fibronectin (5 µg/ml) was determined and plotted
relative to unstimulated, mock-transfected cells. Representative data from experiments performed in triplicate are
shown with error bars representing SD. The experiments were repeated (Rap1GAPII, at least four times; Rap1GAPI
and RBD, twice) with identical results. (Top right) Luciferase counts of total input cells per well in the above
experiment are shown with error bars representing SD of triplicates. (Bottom left panel) Expression of HA-Rap1GAPs
in the above experiment is shown.
motif bind to β1 integrins and have been shown
to block fibronectin binding in ovarian
carcinoma cells (16). As expected, 8CPT-2Me-
cAMP-induced attachment to fibronectin was
abolished (Fig. 2d). 8CPT-2Me-cAMP did not
increase the integrin-independent adhesion of
Ovcar3 cells to poly-L-lysine (Fig. 2e). From
these results we conclude that activation of
endogenous Epac induces integrin-mediated cell
adhesion to fibronectin. 8CPT-2Me-cAMP
enhanced cell adhesion to fibronectin and
induced Rap1 activation at comparable
concentrations (EC50, ~ 30 µM) (Fig. 3a). In a
time-course analysis, we noted that increased
adhesion was already observed after 30 min,
which correlated with a rapid and sustained
Rap1 activation (Fig. 3b). As expected, the
induction of adhesion and activation of Rap1
were insensitive to the PKA inhibitor H-89 (Fig.
3c). However, even low levels of Rap1GAPII
completely inhibited cAMP-induced adhesion
of Ovcar3 cells to fibronectin (Fig. 3d, left
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Figure 4. Stimulation of the
β2-AR with isoproterenol
induces cell adhesion. a,
I s o p r o t e r e n o l  i n d u c e s
adhesion to fibronectin. Ovcar3
cells transiently transfected
with CMVluciferase plasmid
were treated with increasing
concentrations of the β2-AR
agonist isoproterenol, and cells
adhering to fibronectin (2
µg/ml) were quantified as
described in Materials and
methods. b , Isoproterenol
induces activation of Rap1 and
CREB. (Top) Ovcar3 cells
were treated with increasing
concentrations of isoproterenol
for 5 min. Cells were lysed,
and equal amounts of cell
lysate were analyzed for
activation of Rap1 (top) and
CREB (bottom). Total levels of
Rap1 in cell lysates are shown
(middle blot). (Bottom) Cells
were treated with 10 µM of
isoproterenol for the indicated
times. Cells were lysed, and
equal amounts of cell lysate
were analyzed for activation of
Rap1 (top blot) and CREB (bottom blot). Total levels of Rap1 in cell lysates are shown (middle blot). c, Isoproterenol-
induced adhesion to fibronectin is independent of PKA. (Top) Ovcar3 cells were pretreated with H-89 as described in
the legend to Fig. 1 c and seeded onto wells in the absence or presence of isoproterenol (100 µM). Cells were
allowed to adhere for 1 h, and nonadherent cells were removed. The percentage of adherent cells was quantified
and plotted relative to unstimulated cells (range from 2–10%). The plot shown is representative of two (long
pretreatment) and four (short pretreatment) experiments, each in triplicate. Error bars represent SD. (Bottom) Cells
were pretreated with either DMSO or H-89 for 30 min before trypsinization and during the recovery period (DMSO
and long H-89 treatment, respectively) or during the last 30 min of recovery (short H-89 treatment). Then cells were
stimulated with either 50 µM 8CPT-2Me-cAMP for 10 min or isoproterenol for 2 min, respectively. Cells were
centrifuged, cell pellets were lysed, and equal amounts of cell lysate were incubated with precoupled GST-RalGDS-
RBD, and activation of Rap1 was analyzed on Western blot using a Rap1 antibody. d, Isoproterenol-induced
adhesion to fibronectin is inhibited by Rap1GAPII. Ovcar3 cells were transfected with either mock DNA (Vector) or
HA-Rap1GapII alone or in combination with a β2-AR expression vector where indicated. Adhesion of cells to
fibronectin in the absence or presence of isoproterenol was quantified. The percentage of adherent cells was plotted
relative to unstimulated, mock-transfected cells (range 5–15%). Summarizing data of four (for the left half of the plot)
and two (for the right half of the plot) independent experiments performed in triplicate are shown with error bars
representing SD.
plot).  Furthermore, the Rap1-inhibitory
proteins Rap1GAPI and Ras-binding domain
(RBD) of Ral guanine nucleotide dissociation
stimulator (RalGDS) (9) also inhibited adhesion
to fibronectin (Fig. 3d, left plot). Transfection
of cells with Rap1GAPs or RBD of RalGDS did
not affect luciferase expression (Fig. 3d, right
plot).
Our observations that cAMP analogs could
induce adhesion of Ovcar3 cells to fibronectin
prompted us to test whether cAMP-elevating
receptors could also mirror the same effect,
thereby linking an in vivo cAMP signalling
system to integrin activation. The β2-adrenergic
receptor (β2-AR) couples to Gα s type of
heterotrimeric G proteins, resulting in elevation
of intracellular cAMP levels and subsequent
activation of PKA and Epac1-Rap1 signalling
cascades (22,23). Ovcar3 cells endogenously
express the β 2-AR and stimulation with
isoproterenol, a ligand for the β2-AR receptor,
significantly increased adhesion to fibronectin
(Fig. 4a). Treatment with isoproterenol also
induced both activation of Rap1 and
phosphorylation of CREB (Fig. 4b; EC50 for
Rap1 activation and adhesion, ~0.05 µM).
Isoproterenol-induced adhesion was insensitive
to short pre-treatments with H-89 (Fig. 4c,
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Short), but was partially inhibited when
exposed very early to H-89 (Fig. 4c, Long).
Therefore, we looked at activation of Rap1
under similar conditions. We observed that after
early (Fig. 4c, Long)  pretreatment with H-89,
isoproterenol-induced Rap1 activation was
clearly inhibited, whereas 8CPT-2Me-cAMP-
induced Rap1 activation was not (Fig. 4c,
bottom). Since both 8-Br-cAMP-induced and
8CPT-2Me-cAMP-induced adhesion were not
blocked by H-89 (Fig. 1c and 3c), the effect of
very early treatment of H-89 on β2-AR
signalling could likely be attributed to slow
recovery and expression of the β2-AR on the
cell surface. This possibility is consistent with
the observation that PKA is involved in vesicle
fusion (24). Transient transfection of Ovcar3
cells with the β2-AR receptor further enhanced
the isoproterenol-induced adhesion to
fibronectin, which was sensitive to the Rap1-
inactivating protein, Rap1GAPII (Fig. 4d),
showing a critical involvement of Rap1.
Our results demonstrate a clear connection
between cell surface receptors that induce
cAMP, cAMP signalling and integrin-mediated
cell adhesion and show that this pathway is
independent of PKA, but mediated by the
cAMP-target Epac and the small GTPase Rap1.
This conclusion is based on the observations
that isoproterenol, which raises cAMP levels
through activation of endogenous β2-AR, is able
to induce integrin-mediated cell adhesion to
fibronectin in a Rap1-dependent, PKA-
independent manner. Furthermore, importantly,
a cAMP analogue that specifically activates
Epac but not PKA is also able to induce cell
adhesion. However, our results do not entirely
exclude a role for PKA in this process. Both
Rap1 and Rap1GAP are substrates for PKA (4),
and thus PKA may modulate the effect of the
Epac-Rap1 signalling pathway on the adhesion
process.
This novel function of cAMP was found in
Ovcar3, an ovarian carcinoma cell line that
expresses the fibronectin-binding integrin α5β1,
and in NIH3T3 cells stably transfected with
Epac1 (unpublished data). However, the effect
may be more general and may include different
cell types expressing Epac. Epac is particularly
highly expressed in ovary, thyroid, kidney,
adrenal gland and brain (1,25), and it is
expected that the cAMP-Epac pathway leading
to integrin activation may operate particularly in
these tissues. In addition, Rap1 is implicated in
the activation of a variety of integrins, including
αLβ2 and αIIbβ3, and thus the effect may not
be restricted to α5β1 integrins. The regulation
of integrin-mediated adhesion plays an
important role in many cellular processes
including cell migration, cell division, and
reactions to mechanical stress, and cAMP may
impinge on these processes by activation of the
Epac-Rap1 pathway. In ovarian cancer cells, for
instance, functional integrins and molecular
events that regulate them are important for
invasion into the sub-mesothelial ECM
((16,17,26); reviewed in (27)).
How Rap1 regulates integrin-mediated cell
adhesion remains elusive. Integrin activity is
regulated through various mechanisms,
including cell surface expression (change of
number), redistribution at the cell surface
(change of avidity), and conformational changes
(change of affinity) (12,27-30). Studies using
activation-specific antibodies show that Rap1
regulates both avidity and affinity but not cell
surface expression. For instance, in Jurkat cells
Rap1 inhibits both the clustering and the
increased affinity of αLβ2 (8,9,12), whereas in
megakaryocytes Rap1 increases the affinity of
αIIbβ3 (14). In addition, Rap1 is required for
the direct activation of integrins by integrin-
activating antibodies or manganese ions (11).
Apparently, Rap1 modulates a process before
integrin activation, for instance, the recruitment
of an essential cofactor. Interestingly, it has
recently been reported that Rap1 is essential in
the formation of adherens junctions, though it is
less clear whether the process involves integrin-
mediated signalling (31).
Materials and Methods
Cells, plasmids, transfections
 NIH-Ovcar3 (Ovcar3) cells were maintained at 37 oC in
RPMI 1640 supplemented with 10% heat-inactivated (30 min
at 56oC) fetal bovine serum and 0.05% glutamine in the
presence of penicillin and streptomycin. Haemagglutinin
(HA)-tagged constructs of Epac1 and Rap1GAPII in the
PMT2HA expression vector have been described previously
(1,11). Transient transfection of Ovcar3 cells was performed
using the FuGENE 6 transfection reagent (Roche Diagnostics
Corporation ) according to the manufacturer's procedures,
using 6 µg total DNA including either a TK-luciferase
plasmid (1 µg) or CMV-luciferase plasmid (0.2 µg) as
indicated. Cells were serum-starved at least 16 h prior to
stimulation.
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Reagents
 Western blotting of protein samples was carried out
using polyvinylidene difluoride membranes. Antibodies
against dually phosphorylated p42/44M A P K  and
phosphorylated CREB (directed against phosphorylated
Ser133) were obtained from Cell Signalling and antibodies
against K-Rev/Rap1 and polyclonal anti-HA were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The
following inhibitors and stimuli were used at concentrations
indicated: RGD peptide (100 µM) and H-89 (10 µM),
obtained from Biomol Research Laboratories Inc. (Plymouth
Meeting,). Isoproterenol (10 µM, unless indicated otherwise)
was obtained from Sigma-Aldrich and 8-Br-cAMP (1 mM,
unless indicated otherwise) and 8CPT-2Me-cAMP (100 µM,
unless indicated otherwise) from Biolog Life Science
Institute.
Adhesion Assay
24-well plates were coated overnight with fibronectin
(Sigma-Aldrich; 1-5 µg/ml as indicated) in sodium
bicarbonate buffer (Sigma-Aldrich). Poly-L-lysine was coated
for 2 h at RT (0.1% w/v in water), washed twice with water,
and dried overnight. Plates were washed in TSM buffer (20
mM Tris-HCl pH 8, 150 mM NaCl, 1 mM CaCl2, 2 mM
MgCl2) and blocked for 30-45 min at 37
oC with 1%
BSA/TSM. Transiently transfected Ovcar3 cells, serum
starved 16 h before the adhesion assay, were detached by
trypsinization. Cells were centrifuged at 1,500 rpm for 5 min
and resuspended in serum-free RPMI containing 25 mM
Hepes, 0.5% BSA and 1 g/L glucose to allow recovery of cell
surface markers at 37oC for 1.5-2 h with gentle rotation in
suspension. Cells were centrifuged, counted and resuspended
at 3 x 105 cells/ml in serum-free RPMI with 0.5% BSA. The
experiment was carried out in triplicates, and to each well 150
µl of cells was added to 150 µl of medium with or without
stimulus. In studies with H-89 (10 µM), cells were either
preincubated at 37oC for 30 min with the inhibitor before
seeding the wells (short pretreatment) or H-89 was added
before trypsinization, during the recovery period, and before
seeding wells (long pretreatment). Cells were allowed to
adhere for 1 hour at 37oC and non-adherent cells were
removed by gently washing plates three times with warmed
0.5% BSA/TSM. Adherent cells were lysed in luciferase lysis
buffer (15% glycerol, 25 mM Tris-phosphate pH 7.8, 1%
Triton X-100, 8 mM MgCl2, 1 mM DTT) at 4
oC for 30 min,
and units of luciferase activity were quantified with addition
of equal volume of luciferase assay buffer (25 mM Tris-
phosphate pH 7.8, 8 mM MgCl2, 1 mM DTT, 1 mM ATP,
pH7, 1 mM luciferin) using a luminometer (Lumat LB9507;
Berthold technologies). Unseeded cells (150 µl) were lysed
separately to determine luciferase counts in the total input
cells. Specific adhesion (%) was determined (counts in cells
bound/ counts in total input x 100) and plotted either directly
or relative to the basal adhesion of HA vector-transfected
cells. Error bars represent average deviation among
experiments, and where representative experiments are
depicted error bars represent standard deviation within each
experiment. The expression of transfected constructs was
confirmed by immunoblotting of total cell lysates.
Rap1 activation assay and phosphorylation of ERK and
CREB
Rap1 activation assays were performed as described
previously (32,33). Briefly, adherent cells (unless stated
otherwise) were serum starved overnight, treated, and lysed in
750 µl lysis buffer (10% glycerol, 1% Nonidet P-40, 50 mM
Tris-Cl pH7.5, 200 mM NaCl, 2 mM MgCl2, 1 µM leupeptin,
0.1 µM aprotinin, 5 mM NaF, 1 mM NaVO3). Lysates were
clarified by centrifugation and 500 µl of lysate was incubated
with GST-tagged RBD of RalGDS precoupled to glutathione
beads to specifically pull down the GTP-bound forms of
Rap1. Samples were incubated for 1 hr at 40C while tumbling.
Beads were washed four times in lysis buffer, and remaining
fluid was removed with an insulin syringe. Proteins were
eluted with Laemmli sample buffer and analyzed by SDS-
PAGE and Western blotting using Rap1 antibodies (Santa
Cruz Biotechnology, Santa Cruz Biotechnology, Inc). To 100
µl of clarified lysate 25 µl 5x Laemmli sample buffer was
added, and phosphorylation of ERKs was analyzed by
Western blotting using the phospho-specific antibody against
p42/44MAPK. Phosphorylation of CREB was analyzed by
Western blotting using a phospho-specific antibody directed
against phosphorylated Ser133.
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Cyclic adenosine 3’,5’-monophosphate (cAMP) controls a wide range of cellular
responses to many hormones and neurotransmitters, mainly through protein kinase
A (PKA). However, recently Epac, a novel cAMP receptor, was identified. Epac is a
guanine nucleotide exchange factor for the Ras-like small GTPases Rap1 and 2.
Here we show that cAMP, through Epac, regulates the p70/85 ribosomal S6 kinase
(p70S6K). Treatment of Ovcar3 cells with 8-Br-cAMP resulted in phosphorylation
of p70S6K as well as its downstream target ribosomal S6. Furthermore, the Epac-
specific cAMP analogue 8-(4-Chloro-phenylthio)-2’-O-methyladenosine-3’,5’-cyclic
monophosphate (8CPT-2Me-cAMP), which only targets Epac but not PKA, also
increased phosphorylation of p70S6K and S6. This effect was sensitive to the PI3K
inhibitors wortmannin and LY294002, and to the mTOR inhibitor rapamycin.
Cyclic AMP treatment of Ovcar3 cells neither resulted in increased phosphorylation
of PKB, GSK3, and eIF4E-BP1, nor did it result in Rac activation. We conclude that
cAMP activates p70S6K through Epac. Although Epac-induced activation of
p70S6K requires PI3K- and mTOR activity, it might not activate the PI3K pathway.
cAMP was the first identified second
messenger (1). A large number of studies have
elucidated the fundamental role of cAMP in the
wide range of cellular responses to many
hormones and neurotransmitters. Protein Kinase
A (PKA) was the first target of cAMP to be
discovered (2), and was long thought to be the
only mediator of cAMP signalling. However,
widespread expression of cyclic nucleotide
gated (CNG) channels has been demonstrated,
which, like the closely related pacemaker
channels, increase membrane conductance of
cations like calcium upon binding of cAMP or
cGMP (3-5). Furthermore, Epac, exchange
protein directly activated by cAMP (also known
as cAMP-GEF), has been identified, which is a
widely expressed guanine nucleotide exchange
factor (GEF) for the small Ras-like GTPases
Rap1 and Rap2 (6,7).
Rap1 functions as a molecular ‘switch’
that cycles between an inactive GDP and an
active GTP-bound conformation. GEFs ‘switch
on’ the GTPases, whereas GTPase activating
proteins (GAPs) function as ‘off switches’.
Rap1 received much attention since it was
identified in a screen that could revert the K-Ras
transformed phenotype of NIH3T3 cells (8).
This resulted in a model in which Rap1 would
function as an inhibitor of Ras by trapping Ras
effectors in an inactive complex (9-14).
However, recent studies have excluded a role
for Rap1 in ERK signalling ((15); chapter 2).
Rather, Rap1 has a function of its own. Indeed,
Rap1 has been shown to regulate integrins and
thereby cell adhesion ((16-22); chapter 3).
In some cell systems cAMP inhibits cell
proliferation, whereas in other cell types cAMP
acts as a mitogen. For instance, in Wistar rat
thyroid (WRT) cells, cAMP-elevating agents
stimulate proliferation in PKA-dependent and
PKA-independent pathways, involving p70/85
ribosomal S6 kinase (p70S6K) and phosphatidyl
inositol 3-kinase (PI3K) (23,24). p70S6K is
involved in cell cycle progression (25) and it
regulates mitogen-induced translation of 5’ TOP
mRNAs, most likely through phosphorylation of
the ribosomal protein S6 on multiple residues
(26,27). Regulation of p70S6K is complex, and
requires PI3K and PDK1 activity, as well as
mammalian target of rapamycin (mTOR)
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Figure 1. Phosphorylation of a 30 kDa protein
corresponding to S6 after treatment with
8CPT-2Me-cAMP. a, treatment of Ovcar3 cells
with 8CPT-2Me-cAMP induces phosphorylation
of a 30 kDa protein. Cells were treated with
increasing concentrations of 8CPT-2Me-cAMP
for 10 min, lysed, and equal amounts of protein
were analyzed for phosphorylation by Western
blotting using an anti-phospho-PKB-substrate
antibody (upper panel). Furthermore, equal
amounts of cell lysate were checked for Rap1
activation (middle panel) and phosphorylation of
CREB (lower panel). As a positive control for
CREB phosphorylation, cells were treated with
forskolin (F) for 10 min. b, phosphorylation of the
30 kDa protein is inhibited by H-89. Ovcar3 cells
were pretreated for 30 min with increasing
concentrations of H-89 as indicated, and treated
with 8CPT-2Me-cAMP for 10 min where
indicated. Cells were lysed and equal amounts
of cell lysate were analyzed for phosphorylation
using an anti-phospho-PKB-substrate antibody.
c, 8CPT-2Me-cAMP induces PI3K-dependent
phosphorylation of S6. Ovcar3 cells were pretreated with LY294002 for 30 min where indicated and subsequently
treated with 8CPT-2Me-cAMP for the indicated times. Equal amounts of cell lysate were analyzed for
phosphorylation of S6 using phospho-specific S6 antibodies.
activity (28). Recent studies have indicated that
the tuberous sclerosis (TSC) gene products,
TSC1 (hamartin) and TSC2 (tuberin), are
regulated by PI3K and function as upstream
regulators of mTOR and p70S6K (29-34). In
parallel, mTOR also stimulates mRNA
translation. It phosphorylates the eukaryotic
initiation factor 4E binding protein 1 (eIF4E-
BP1), which in resting state forms an inactive
complex with eIF4E. Upon phosphorylation,
eIF4E-BP1 dissociates, and eIF4E subsequently
increases mRNA translation (35). In contrast to
the acute phosphorylation of both p70S6K and
eIF4E-BP1, the effects of mitogens on mTOR
are small and controversial, and the exact
mechanism of regulation of mTOR function has
been questioned (35,36). In addition, activity of
mTOR is regulated by carbon and nitrogen
sources, which influence ATP levels in the cell,
and therefore mTOR has been proposed to
function as an ATP sensor (37). Cyclic AMP
has been reported to stimulate p70S6K activity
(23,24). Furthermore, Epac has been implicated
in cAMP induced activation of PI3K and PKB,
upstream regulators of p70S6K (38). Therefore,
we investigated the possibility that Epac can
mediate the stimulatory effects of cAMP on
p70S6K. We show that treating Ovcar3 cells
with either 8-Br-cAMP or 8CPT-2Me-cAMP, a
cAMP analogue that specifically targets Epac
and not PKA, results in phosphorylation of
p70S6K and S6. Furthermore, we show that this
effect of cAMP is dependent on activity of the
PI3K and the mTOR pathways, since 8CPT-
2Me-cAMP-induced p70S6K activation was
completely blocked by the PI3K inhibitors
LY294002 and wortmannin, and by the mTOR
inhibitor rapamycin. However, no effect was
observed of 8CPT-2Me-cAMP on the PI3K-
targets PKB, GSK3, and Rac, nor
phosphorylation of the mTOR target eIF4E-
BP1, suggesting that although these pathways
are critically required, 8CPT-2Me-cAMP
activates p70S6K through a different yet
unknown mechanism.
Results
Epac has been reported to be involved in
activation of the PI3K and PKB pathway (38).
Therefore, we searched for a role for PI3K in
Epac-mediated cAMP signalling. We treated
Ovcar3 cells with increasing concentrations of
8CPT-2Me-cAMP, which specifically targets
Epac1 but not PKA (39), and probed whole cell
lysates (WCL) on western blot with a phospho-
PKB-substrate antibody. A protein of
approximately 30 kDa became readily
phosphorylated with similar stoichiometry as
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Figure 2. cAMP induces phosphorylation of p70S6K through Epac1 and requires mTOR- and PI3K-activity.
a, 8-Br-cAMP activates p70S6K. Ovcar3 cells were treated with 1mM 8-Br-cAMP for the indicated times, lysed,
and phosphorylation of p70S6K was analyzed on Western blot by shift (upper panel), or phosphorylation of S6
using phospho-specific S6 antibodies (lower panel). b, inhibition of mTOR and PI3K inhibits 8CPT-2Me-cAMP-
induced p70/p85S6K phosphorylation. Ovcar3 cells were pretreated for 30 min with either rapamycin, wortmannin,
or LY294002, respectively. Subsequently, cells were treated for 5 min with insulin or for 15 min with 8CPT-2Me-
cAMP, lysed, and equal amounts of cell lysate were analyzed for phosphorylation of p70/p85S6K by shift on
Western blot (upper panel), or phosphorylation of S6 ribosomal protein using phospho-specific antibodies (lower
panel). c, amino acid starvation blocks 8CPT-2Me-cAMP-induced phosphorylation of the 30 kDa protein. Ovcar3
cells were incubated for 15 min with PBS ('PBS') or left on medium ('medium') before treatment with 8CPT-2Me-
cAMP or EGF for the indicated times, respectively. Cells were lysed and equal amounts of cell lysate were
analyzed on Western blot for phosphorylation of the 30 kDa protein or for phosphorylation of p42/44 MAPK using
phospho-specific PKB-substrate antibodies or phospho-specific MAPK antibodies, respectively. d, 8CPT-2Me-
cAMP does not induce eIF4EBP1 phosphorylation. Ovcar3 cells were pretreated with inhibitors where indicated
and treated or not treated with 8CPT-2Me-cAMP for 15 min. Lysates were analyzed for eIF4EBP1 phosphorylation
using eIF4EBP1 antibodies.
activation of Rap1 (Fig. 1a). Specificity of
8CPT-2Me-cAMP towards Epac was
confirmed using a phospho-specific CREB
antibody. It should be noted that
phosphorylation of the 30 kDa protein was
subject to variation, and seemed to depend on
culture conditions and cell density, and
possibly other factors, like starvation of cells
for glucose or nitrogen (data not shown).
Surprisingly, pretreatment of cells with the
PKA inhibitor H-89 blocked 8CPT-2Me-
cAMP-induced phosphorylation of the 30 kDa
protein (Fig. 1b). However, 8CPT-2Me-cAMP
even at high concentrations does not activate
PKA ((39); and Fig. 1a), and H-89 not only
inhibits PKA (IC50: 135 nM) but also
efficiently inhibits other kinases with a potency
similar to or greater than that for PKA. For
example, p70S6K, MSK1, ROCK-II and PKB
are inhibited by H-89 with IC50s of 80 nM,
120 nM, 270 nM and 2.6 µM, respectively
(40). Therefore, a direct role for PKA in
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Figure 3. Expression of Rap1 exchange factors
induces S6 phosphorylation. a, NIH3T3-A14 cells
were transfected with exchange factors for Rap1 as
indicated. 48 h after transfections cells were lysed and
equal amounts of cell lysate were analyzed for S6
phosphorylation (upper panel). Expression of proteins
was confirmed using HA antibodies. Expression of
C3G could not be detected since it is not HA-tagged.
b, NIH3T3 cells were transfected as indicated. After 48
h cells were lysed, and a kinase assay was performed
using HA-immunoprecipitated p70S6K.
phosphorylation of the 30 kDa protein is
unlikely. Since H-89 inhibits p70S6K even
more efficiently than PKA, and the S6
ribosomal protein has a MW of approximately
30 kDa, we hypothesized the identity of the 30
kDa protein to be S6. To test this hypothesis
we treated cells with 8CPT-2Me-cAMP and
monitored S6 phosphorylation on Western
blot.  Indeed, S6 becomes readily
phosphorylated upon 8CPT-2Me-cAMP
treatment, which is completely blocked by the
PI3K inhibitor LY294002 (Fig. 1c),
confirming previous results that PI3K activity
is necessary for full p70S6K activity (28).
Taken  toge the r ,  cAMP induces
phosphorylation of S6 through Epac and
requires PI3K activity.
Activation of p70S6K follows
phosphorylation of p70S6K on at least eight
residues (41). Since cAMP treatment results in
phosphorylation of ribosomal S6, we wanted to
investigate p70S6K phosphorylation directly.
Treatment of Ovcar3 cells with 8-Br-cAMP
produced several shifted p70S6K protein bands
on Western, indicating phosphorylation of
p70S6K on multiple sites, and resulted in
concomitant phosphorylation of the ribosomal
S6 protein (Fig. 2a). Furthermore, treatment of
cells with the Epac-specific cAMP-analogue
8CPT-2Me-cAMP induced multiple shifts of
the p70 and p85 S6K isoforms, and
phosphorylation of ribosomal S6 (Fig. 2b).
Pretreating cells with the PI3K inhibitors
wortmannin and LY294002 and the mTOR
inhibitor rapamycin completely abrogated
p70 /p85S6K and  r i bosoma l  S6
phosphorylation, confirming previous studies
showing that S6K activity requires activity of
both the PI3K and the mTOR pathway (28).
Since mTOR is required for activity of
p70S6K, we wanted to investigate whether
Rap1 is involved in regulation of mTOR.
mTOR plays an important role in amino acid
sensing (37,42). Therefore we starved Ovcar3
cells for amino acids by leaving them on PBS
for 15 min. When cells were kept on medium,
stimulation with either 8CPT-2Me-cAMP or
EGF resulted in phosphorylation of the 30 kDa
protein corresponding to ribosomal S6 (Fig. 2c,
upper panel). However, when cells were
stimulated in PBS, neither 8CPT-2Me-cAMP
nor EGF was capable of inducing
phosphorylation. In contrast, EGF treatment of
cells in PBS induced MAPK phosphorylation
just as well as in medium (Fig. 2c, lower
panel). Thus, treatment of cells with 8CPT-
2Me-cAMP does not bypass the requirement
for mTOR-activity to induce full S6
phosphorylation, implying a link between
cAMP and mTOR. Therefore, we investigated
whether 8CPT-2Me-cAMP modulates mTOR
activity directly. However, 8CPT-2Me-cAMP
treatment of Ovcar3 cells did not result in
enhanced phosphorylation of the mTOR target
eIF4E-BP1, as visualized by shift on western
blot, although pre-treatment of cells with
LY294002 and rapamycin, and to a lesser
extent H-89 resulted in decreased
phosphorylation levels compared with
untreated cells (Fig. 2d). Altogether, cAMP
treatment results in p70/85S6K and ribosomal
S6 phosphorylation through the Epac pathway,
most likely involving the small GTPase Rap1.
Furthermore, although the activity of PI3K and
the mTOR pathways are required for S6
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Figure 4. Rap1 does not co-immunoprecipitate with
PI3Kγ and does not induce phosphorylation of PKB
and GSK3. a, HA-Rap1bV12 does not co-
immunoprecipitate with PI3Kγ. HEK293T cells were
transfected as indicated. 48 hrs after transfection cells
were lysed and either HA-tagged or Myc-tagged
proteins were immunoprecipitated from equal amounts
of cell lysate. Co-immunoprecipitation was checked on
Western blot using antibodies against Myc or HA,
respectively (upper two panels). Expression of proteins
was confirmed using HA and Myc antibodies (lower two
panels). b , 8CPT-2Me-cAMP does not induce
phosphorylation of PKB. Ovcar3 cells were treated with
either EGF or with 8CPT-2Me-cAMP for the indicated
times. Cells were lysed and equal amounts of cell
lysate were analyzed for phosphorylation of PKB using
phospho-specific antibodies against T308 or S473,
respectively. c,  cAMP does not induce GSK3
phosphorylation. Ovcar3 cells were pretreated for 30
min with either LY294002 or H-89 where indicated.
Subsequently, cells were stimulated for 15 min with
either 8CPT-2Me-cAMP, 8-Br-cAMP, or insulin,
respectively. Equal amounts of cell lysate were
analyzed for phosphorylation of GSK3 using a
phospho-specific GSK3 antibody.
phosphorylation, it does not directly activate
mTOR.
In order to confirm that the Rap1-p70S6K
pathway is functional in other cell systems as
well, we transfected A14 cells (NIH3T3 cells
overexpressing the human insulin receptor) with
various RapGEFs. Transfection with PDZ-GEF
gave a modest increase in S6 phosphorylation
(Fig. 3a), whereas both transfection with Epac1
in conjunction with a 10 min forskolin treatment
as well as transfection with C3G resulted in a
more robust S6 phosphorylation. Furthermore,
to directly assess p70S6K kinase activity we
transfected A14 cells with increasing
concentrations of p70S6K cDNA in absence or
presence with equal amounts of C3G cDNA. As
shown in Fig 3b, p70S6K is much more active
when C3G is co-transfected, indicating that co-
transfection of C3G boosts p70S6K activity. In
conclusion, in NIH3T3 cells, transfection of
RapGEFs results in an increase of p70S6K
activity as well as S6 phosphorylation,
indicating that activation of Rap1 results in
activation of p70S6K.
Since cAMP-induced p70S6K activation
requires PI3K activity, and PI3Kγ  has
previously been shown to bind H-Ras through
its Ras Binding Domain (RBD) (43), and since
Rap1 has an identical effector domain as Ras,
we wanted to know whether Rap1 can also
directly interact with this PI3K isoform.
However, in transiently transfected HEK293T
cells, only H-RasV12 co-immunoprecipitated
with PI3Kγ, whereas Rap1V12 and, as a control,
H-RasN17 did not (Fig. 4a). Furthermore, PKB
and GSK-3, in vivo downstream targets of PI3K,
did not get phosphorylated when Ovcar3 cells
were treated with 8CPT-2Me-cAMP, whereas
EGF treatment clearly resulted in
phosphorylation of these proteins (Fig. 4b and
4C, respectively). Finally, Rac, a small GTPase
which is also activated in a PI3K-dependent
manner, and which previously has been reported
to be activated by cAMP (44,45), was neither
activated by 8CPT-2Me-cAMP nor by forskolin
in Ovcar3 cells and Chinese Hamster Ovary E14
(CHO-E14) cells (Fig. 5a). Since cAMP-
induced Rac activation could be transient,
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Figure 5. cAMP does not activate Rac in Ovcar3
cells and in CHO-E14 cells. a, cAMP does not
activate Rac. CHO-E14 cells (upper panel) and Ovcar3
cells (lower panel) were transfected with Myc-tagged
Rac where indicated. 24 h after transfection cells were
serum starved, and 48 h after transfection cells were
treated with either 8CPT-2Me-cAMP or forskolin for 15
min, lysed, and equal amounts of cell lysate were
analyzed for Rac using Myc antibodies. b, in a time
course, 8CPT-2Me-cAMP does not activate Rac. CHO-
E14 cells (upper panel) and Ovcar3 cells (lower panel)
were transfected with Myc-tagged Rac or Myc-tagged
RacV12 where indicated. 24 h after transfection cells
were serum starved, and 48 h after transfection cells
were treated with 8CPT-2Me-cAMP for the indicated
times or with 20% FCS ('FCS'), where indicated.
Subsequently, cells were lysed and equal amounts of
cell lysate were analyzed for Rac activation using Myc
antibodies. c, Rap1 is activated by cAMP and TPA in
CHO-E14 cells. Cells were serum starved for 24 h,
treated with either 8CPT-2Me-cAMP, 8-Br-cAMP, or
TPA for the indicated times. Subsequently, cells were
lysed, and equal amounts of cell lysate were analyzed
for Rap1 activation.
we also performed a time course of 8CPT-
2Me-cAMP in Ovcar3 cells and CHO-E14
cells (Fig. 5b). As a control, Rap1 was readily
activated upon treatment with either 8CPT-
2Me-cAMP, 8-Br-cAMP, or TPA (Fig. 5c). In
conclusion, although PI3K activity is required
for cAMP-induced phosphorylation of p70S6K
and ribosomal S6, Rap1 most likely does not
directly activate PI3K upon cAMP treatment.
Discussion
Cyclic AMP directly regulates many
cellular processes like for example glucose
metabolism, long-term potentiation, cell cycle
progression, cell adhesion, and hormone
secretion. Cyclic AMP affects many of these
processes through diverse cellular signalling
pathways, like for instance the ERK pathway
(46), the calcium pathway (47,48), and PI3K.
Although PKA was long thought to account for
all of these effects, recently Epac has attracted
much attention. Epac, but also CNG channels,
appear to mediate a number of the effects of
cAMP. For example, Epac has been implicated
in calcium signalling (47-51), hormone
secretion (50,52), and cell adhesion (53).
Furthermore, Epac may play a role in
modulation of the PI3K-PKB pathway (38).
In this study,  we analyzed the ability of
cAMP to activate p70S6K. Both 8-Br-cAMP
and the Epac-specific cAMP analogue 8CPT-
2Me-cAMP increased phosphorylation of
p70S6K and S6 in Ovcar3 cells, indicating that
Epac mediates this effect. Although the
activity of the PI3K and mTOR pathways were
absolutely necessary for cAMP to activate
p70S6K, they did not seem to be activated by
cAMP, since neither the PI3K targets PKB,
GSK3, and Rac, nor the mTOR target eIF4E-
BP1 were affected by cAMP. It should be
noted that there was variation in activation of
p70S6K by cAMP. It is not clear what might
be the cause of this, but culture conditions, cell
density (54), days of cell culturing and thereby
starvation of e.g. carbon or nitrogen (37), or
the extent of cell adhesion and thereby focal
adhesion kinase (FAK) activity (55) may all
play a role. Furthermore, the effect of 8CPT-
2Me-cAMP on S6 was only observed in
Ovcar3 cells, and may therefore be very cell-
type specific (data not shown).
Cyclic AMP has been reported to activate
p70S6K in a number of cell types, including
rat thyroid cells, rat pancreatic cells, and
Swiss3T3 cells (24,56,57). Additionally, cyclic
AMP may activate the PI3K-PKB pathway
through Epac in human embryonic kidney
(HEK) 293 cells (38). Our results indicate a
role for Epac in cAMP-induced p70S6K
activation. How exactly Epac mediates this
effect remains unknown. Activation of Epac
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did not seem to result in activation of the PI3K
pathway or the mTOR pathway, although it
cannot be excluded that activation of Epac
results in activation of a specific, very
localized PI3K, that only signals to p70S6K
but not to PKB (58). Alternatively, although
PI3K and mTOR pathways are clearly
required, Epac may activate p70S6K through a
different mechanism, for example by
inactivating a phosphatase (59), or by
activating integrins, which results in outside-in
signaling (55).
The effect of cAMP on PKB seems to be
the result of a balance between the inhibiting
activity of the PKA pathway and the activating
activity of the Epac pathway (38). There is
considerable cross-talk between cAMP
signalling pathways (47,48). Regulation of
p70S6K by cAMP therefore may be complex
and subject to several cAMP-regulated
pathways.
Materials  and methods
Cells, plasmids, transfections
NIH-Ovcar3 (Ovcar3) cells and HEK293T cells were
maintained at 37oC in RPMI 1640, NIH3T3-A14 cells were
maintained in DMEM. All media were supplemented with
10% heat-inactivated (30 min at 56oC) fetal bovine serum and
0.05% glutamine, in the presence of penicillin and
streptomycin. Expression vector for C3G was a generous gift
from dr. Michiyuki Matsuda (International Medical Center of
Japan, Tokyo, Japan), expression vectors for Myc-tagged
PI3Kγ and S6 cDNA were generously provided by dr. Phil
Hawkins (The Babraham Institute, Babraham, Cambridge
CB2 4AT, UK) and dr. George Thomas (Friedrich Miescher
Institute, Basel, Switzerland), respectively. HA-tagged
constructs of Epac1, PDZ-GEF,  Rap1bV12, H-RasV12, H-
RasN17 have been described previously (7,17,18,60).
Transient transfection of HEK293T cells was performed using
the FuGENE 6 transfection reagent (Roche Diagnostics
Corporation) according to the manufacturer's procedures,
using 5 µg total DNA. NIH3T3-A14 cells were transfected by
the calcium phosphate method.
Reagents
The following inhibitors and stimuli were used at
concentrations indicated: H-89 (10 µM), LY294002 (10 µM)
and rapamycin (10 nM) were all from Biomol Research
Laboratories Inc, Plymouth Meeting, PA, USA; wortmannin
(100 nM), insulin (1 µg/ml) and EGF (20 ng/ml) were from
Sigma; Forskolin (25 µM; ICN, Costa Mesa, CA, USA); 8-
Br-cAMP (1 mM) and 8CPT-2Me-cAMP (100 µM, unless
indicated otherwise) were from Biolog Life Science Institute,
Bremen.
Antibodies
Western blotting of protein samples was carried out
using polyvinylidene difluoride membranes. Antibodies
against dually phosphorylated p42/44MAPK, phospho-CREB,
phospho-S6, phospho-PKB (S473 or T308), phospho-GSK3,
and a phospho-PKB-substrate antibody were all obtained from
Cell Signalling Technology. Antibodies against K-Rev/Rap1
and p70S6K were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Haemagglutinin (HA)-tagged
proteins were immunoprecipitated and detected with
monoclonal HA antibodies (12CA5), Myc-tagged proteins
were immunoprecipitated and detected with monoclonal Myc
antibodies (9E10).
Rap1 activation assay
Rap1 activation assays were performed as described
previously (61,62). Briefly, cells were treated, lysed in 750
µl lysis buffer (10% glycerol, 1% Nonidet P-40, 50 mM Tris-
Cl pH7.5, 200 mM NaCl, 2 mM MgCl2, 1 µM leupeptin, 0.1
µM aprotinin, 5 mM NaF, 1 mM NaVO3). Lysates were
clarified by centrifugation and 500 µl of lysate was incubated
with GST-tagged Ras Binding Domain of RalGDS pre-
coupled to glutathione beads to specifically pull down the
GTP-bound forms of Rap1. Samples were incubated for 1 hr
at 40C while tumbling. Beads were washed four times in lysis
buffer, remaining fluid was removed with an insulin syringe.
Proteins were eluted with Laemmli sample buffer and
analyzed by sodium dodecyl sulphate (SDS)-polyacrylamide
gel electrophoresis and Western blotting using Rap1
antibodies. To 100 µl of clarified lysate 25 µl of 5x Laemmli
sample buffer was added and phosphorylation of proteins was
analyzed by Western blotting using phospho-specific
antibodies, phosphorylation of p70S6K and p85S6K isoforms
were analyzed by shift on Western blot using p70S6K
antibodies, which also recognize the p85S6K isoform.
Immunoprecipitation
HEK293T cells were lysed in lysis buffer containing
10% glycerol, 1% Nonidet P-40, 50 mM Tris-Cl pH7.5, 200
mM NaCl, 2 mM MgCl2, 1 µM leupeptin, 0.1 µM aprotinin, 5
mM NaF, 1 mM NaVO3 and transfected proteins were
immunoprecipitated using antibodies against HA or Myc
precoupled to protein G-sepharose beads for three hours at
40C. Beads were washed four times with lysis buffer and
proteins were eluted with 1x laemmli sample buffer followed
by SDS-PAGE and Western blotting.
Kinase assay
Cells transfected with cDNA encoding HA-tagged
p70S6K were washed twice with ice-cold lysis buffer (NaCl
120 mM, Tris 50 mM pH7.5, EDTA 1mM, EGTA 6 mM,
NaF 20 mM, benzamidine 1 µM, pyrophosphate (NaPPi) 15
µM, and para-nitrophenylphosphate (pNPP) 30 µM). Cells
were lysed in lysis buffer supplemented with Nonidet P-40
1%. Cell lysates were precleared with pre-immune rabbit
antibody precoupled to prot-A agarose beads for 15 min at
40C, and p70S6K was immunoprecipitated for 2.5 hrs at 40C
using the HA antibody 12CA5 precoupled to prot-A agarose
beads. Subsequently, beads were washed with ice-cold lysis
buffer for three times and once with ice-cold dilution buffer
(MOPS 20 mM, Triton X-100 0.2%, and MgCl2 10 mM).
After resuspending beads in 5 µl dilution buffer
supplemented with DTT 1 mM, and 5 µl reaction mix (ATP
34 µM, DTT 340 µM, MOPS (pH7.2) 17 mM, MgCl2 3.4
mM, pNPP 3.4 µM, PKI 0.25 µg, p70S6K Rsk substrate
peptide (Santa Cruz Biotechnology) 4 µg, and γ-32P-ATP),
they were incubated at 300C for 15 min and tumbled
occasionally. Reaction was stopped by adding Laemmli
sample buffer.
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Cyclic AMP, in 1956 by Earl Sutherland
the first second messenger to be discovered,
regulates a wide variety of cellular processes in
response to many neurotransmitters and
hormones. Since the identification of PKA (1) it
was long thought that all the effects of cAMP
were solely executed through this kinase.
Therefore it came as a surprise when an ion
channel was discovered that was also regulated
by direct binding of cAMP (2). Since then two
families of cyclic nucleotide-regulated ion
channels have been identified: cyclic
nucleotide-gated ion channels (CNG channels),
and hyperpolarization-activated and cyclic
nucleotide-gated channels (HCN channels, also
known as pacemaker channels) (3-5). More
recently Epac, a third direct cAMP-target, has
been discovered (6,7). Epac is an exchange
protein for the small Ras-like GTPases Rap1
and Rap2. Cyclic nucleotide-regulated ion
channels and Epac may participate in a number
of cAMP-regulated cellular processes that were
originally thought to be executed solely through
PKA, like for example cell proliferation, cell
adhesion, regulation of calcium levels, and
hormone secretion.
Cyclic AMP and cell proliferation
A well-known effect of cAMP is
regulation of proliferation. In some cell types
cAMP inhibits proliferation, whereas in other
cell types it stimulates proliferation. In cells in
which cAMP inhibits proliferation, it also
inhibits growth factor-induced ERK activation
(8,9). Recently, this effect of cAMP has been
claimed to be mediated by the small GTPase
Rap1 (10,11), which can form an inactive
complex with Raf1 (12,13). In this model,
cAMP activates Src through PKA, upon which a
complex of Cbl, Crk, and the Rap1-GEF C3G
assembles and Rap1 is activated. However,
PKA-mediated activation of Src has recently
been debated (14). Furthermore, hormone-
induced activation of endogenous Rap1 does not
interfere with Ras signaling (15). Finally, a
cAMP analogue that specifically activates the
Epac1-Rap1 pathway but not the PKA pathway
failed to inhibit growth factor-induced ERK
signaling (chapter 2). Therefore it is unlikely
that cAMP inhibits growth factor induced ERK
signaling through Rap1. Indeed, a number of
recent studies have shown that PKA completely
abolishes growth factor-induced ERK activation
either through direct phosphorylation of Raf1
(16-19), or through phosphorylating and thereby
inhibiting PAK, an upstream activator of Raf1
(20).
How cAMP inhibits cell proliferation is
not clear. Although phosphorylation of Raf1 by
PKA slows down proliferation, it does not block
the cell cycle (16). Therefore, cAMP probably
also targets other cell cycle regulators. For
instance, cAMP increases levels of the cell cycle
inhibitor p27K i p 1  in macrophages (21).
Furthermore, in addition to p27Kip1 levels,
cAMP also suppresses cyclin D3 levels in
leukemic T cell lines (22). cAMP also activates
the transcriptional repressor ICER, which has
anti-tumorigenic and cell cycle inhibiting
activity by inhibiting expression of c-fos and
cyclin A ((23) and references therein). Since
PKA substrate motifs and CREs are widespread,
most likely many other ways of cAMP to
control cell proliferation exist.
In certain cell lines cAMP stimulates cell
proliferation and activates Erk. The fact that in
one cell line cAMP stimulates Erk, whereas in
others it inhibits Erk signaling, has been
explained by expression of different Raf
isoforms. In cells expressing Raf1, cAMP would
inhibit Erk signaling by promoting formation of
an inactive Rap1-Raf complex, whereas in cells
expressing the B-Raf isoform, cAMP would
activate Erk. In contrast to the Rap1-Raf1
complex, the Rap1-B-Raf complex is active
(24), and therefore Rap1 has been suggested to
be mediating cAMP-induced Erk activation
(25,26). This model is supported by a large
number of reports (27-46). However, recent
studies indicate that endogenous Rap1 may not
be involved in cAMP-induced ERK activation,
but rather point towards a role for PKA and
possibly Ras (15,47-53). Indeed, a cAMP
analogue that specifically targets Epac-Rap1 but
not PKA, did not result in Erk activation, and
overexpression of dominant negative RasS17N,
but not the Rap inhibitor Rap1GAPI blocked
cAMP-induced Erk activation (chapter 2).
Therefore, Rap1 is unlikely to be involved in
Erk regulation. How cAMP would activate Erk
is unknown. Several mechanisms have been
suggested, including inactivation of an Erk
phosphatase by PKA, and PKA-independent
regulation of Ras (47,53), although it remains
elusive which Ras-GEF would mediate the
cAMP signal.
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Another potential mediator of cAMP-
stimulated cell proliferation is the PI3K
pathway. PI3K, and its targets PKB and p70S6K
are involved in regulation of cell proliferation
and survival (54-56). One of the best studied
model systems for the effect of cAMP on cell
proliferation is the thyroid cell system. In these
cells cAMP-elevating agents stimulate
proliferation in PKA-dependent and PKA-
independent pathways, involving PI3K and
p70S6K (57,58). Since ectopic expression of
PKA does not mimick cAMP-induced thyroid
cell proliferation (59), other cAMP pathways
must also play a role, and although the
involvement of the Epac-Rap1 pathway remains
unclear from these studies, cAMP efficiently
activates Rap1 in thyroid cells (60). Whether
Rap1 is indeed the missing link in cAMP-
induced cell proliferation remains to be
investigated. Interestingly, in Ovcar-3 cells
cAMP may stimulate the activity of p70S6K
through the Epac pathway, although the
mechanism remains unknown (chapter 4).
Recently, the tuberous sclerosis gene products
TSC1 and TSC2 have been identified as
upstream regulators of p70S6K (61-66). TSC1
and TSC2 function in a complex to repress
p70S6K activity, and upon phosphorylation by
PKB, TSC2 has been suggested to become poly-
ubiquitinated and targeted for the proteasome.
Epac has been reported to activate PI3K and
PKB, possibly through Rap1 (67). Therefore, it
would be tempting to speculate that Epac
regulates p70S6K through a pathway involving
Rap1, PI3K, PKB, and TSC2. However, no
increase in PKB phosphorylation was observed
after treatment with 8CTP-2Me-cAMP (chapter
4). Alternatively, cAMP may activate p70S6K
in a PKB-independent manner. Indeed, recently,
in thyroid cells cAMP has been reported to
activate p70S6K through PI3K and PDK
without activating PKB (68), although the role
of the Epac pathway remains elusive.
Furthermore, cAMP-Epac may activate p70S6K
in a pathway involving integrins. The cAMP-
Epac-Rap1 pathway increases cell adhesion by
activating integrins (chapter 3), which in turn
may result in ‘outside-in’ signalling, resulting in
activation of p70S6K (69).
Cross-talk between the cAMP pathways
may explain some of the effects of cAMP. For
instance, in a recent report Rap1 has been
suggested to cooperate with PKA in cAMP-
induced DNA synthesis and thyroid cell
proliferation (70,71) Furthermore, in HEK293
cells, cAMP activates PKB through a pathway
involving Epac and PI3K, whereas PKA has an
inhibiting effect on PKB (67).
In conclusion, whereas cAMP-mediated
inhibition of cell proliferation and Erk signaling
generally is executed only through PKA, in
specific cell types Epac and PKA might act in
concert to regulate cell proliferation through
other signaling pathways, like for instance the
PI3K pathway.
Cyclic AMP and cell adhesion
Several studies suggest a role for cAMP
in cell adhesion. For instance, cAMP inhibits
adhesion of neutrophils to human umbilical vein
endothelial cells (HUVECs) (72,73). On the
other hand, it stimulates adhesion of other cell
types, like lymphocytes (74), thymocytes (75),
and HT-1080 human fibrosarcoma cells (76).
Thus far, all the positive and negative effects of
cAMP on cell adhesion have been attributed to
PKA. However, cAMP may also stimulate cell
adhesion through the Epac-Rap1 pathway
(chapter 3). Rap1 appears to be a key regulator
of integrin activity (78-89). Many if not all
integrins respond to Rap1 acivity, including the
ICAM and VCAM receptors αLβ2 and αMβ2,
the fibronectin receptors α4β1 and α5β1, and
the fibrinogen receptor α IIbβ3. How Rap1
activates integrins is unknown, and conflicting
results have been reported. For instance, in
mouse T cells, Rap1 has been suggested to
affect clustering of LFA-1 but not its affinity
(89). In contrast, in T lymphocytes Rap1 has
been reported to modulate LFA-1 affinity (87),
and in B lymphocytes stimulation of both
integrin affinity and avidity by Rap1 has been
reported (86). A recent study suggests that
activation of Rap1 results in polarized cell-
surface expression of proteins involved in cell
adhesion and migration (88). Such a function of
mammalian Rap1 resembles the function of
Bud1, the closest homologue of Rap1 in
budding yeast. Bud1 determines the location of
the new bud site by recruiting cell-polarity
factors CDC24 and CDC42 (90-92). However,
activation of Rap1 by cAMP does not result in
activation of Rac (chapter 4), and therefore the
mechanism of cell polarization by Rap1
probably differs from the yeast mechanism. For
example, Rap1 might regulate vesicle transport,
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since a number of proteins that contain putative
RA or RBD domains also contain domains that
are found in proteins involved in vesicle sorting,
like PH (Pleckstrin homology) domains, PX
(phox) domains, and VPS9 (vacuolar protein
sorting) domains (SMART database). For
example, Sorting Nexin 27 harbours a putative
Ras association domain and a putative PX
domain, which may bind phosphatidylinositol
(PI) lipids and thereby localize the protein to
specific sites in the cell. In addition, Rap1 has
been localized predominantly at intracellular
membranes in the perinuclear region and at
endocytic and exocytic vesicles (93). It is
conceivable that Rap1 regulates integrin
distribution on the cell surface by directing
transport of molecules involved in cell adhesion
from one side of the cell to the other side,
thereby potentiating cell adhesion. It is also
possible that Rap1 facilitates integrin
connections with the cytoskeleton. For example,
overexpression of Rap1 in Dictyostelium
discoideum,  induces changes in the
cytoskeleton, resulting in cell spreading and
flattening (94-96). Furthermore, Rap1 binds the
junctional protein AF-6/Afadin (97), which
localizes to adherens and tight junctions and is
thought to connect cell surface adhesion
molecules with the actin cytoskeleton.
Interestingly, AF-6 can simultaneously bind
Rap1-GTP and the Rap1GAP Spa1, thereby
affecting cell adhesion (98). In Drosophila,
Rap1 and Canoe, the D r o s o p h i l a AF-6
homologue, both affect photoreceptor formation
in the eye, suggesting that they could be in the
same genetic pathway (99,100). Rap1 has also
been shown to regulate localization of adherens
junctions in Drosophila, possibly suggesting
another link between Rap1 and Canoe (101).
However, it is not clear from this study whether
Rap1 regulates tight junction formation directly
or indirectly, for instance via integrins.
Many other processes that require integrin
functions may also be regulated by Rap1. For
example, Rap1 has been implicated in agonist-
induced phagocytosis of opsonized particles by
macrophages (85), morphogenesis and cell
migration in D r o s o p h i l a (102),  and
transmigration of leukocytes through endothelial
monolayers (88). Interestingly, DOCK4, a CDM
family member that regulates intercellular
junctions and is disrupted during tumorigenesis,
has been shown to stimulate Rap1 activation
(103).
Cyclic AMP has differential effects on
many of the processes that require integrin
activity. It remains to be established how cAMP
exerts these effects, and what the exact
contribution of the three cAMP signaling
pathways is.
Cyclic AMP, calcium, and hormone secretion
Cyclic AMP is well known to affect
calcium levels in the cell. cAMP directly binds
CNG-channels and pacemaker channels, thereby
increasing inward calcium conductivity (see for
reviews (3-5)). Furthermore, PKA regulates
calcium levels through direct phosphorylation of
the IP3R (for a review see (104)). Finally, a
number of recent reports indicate the
involvement of the Epac signaling pathway in
regulation of calcium levels. For instance, Epac
might activate PLCε through the small GTPase
Rap2B (105). PLCε contains two putative Ras
binding domains, one of which has been shown
to bind Ras-GTP and Rap-GTP (106-108).
Activation of PLCε results in formation of DAG
and IP3 and subsequent calcium release.
Furthermore, Epac2 may somehow regulate the
RYR-type calcium channels, resulting in
calcium release and hormone secretion
(109,110), but it may also be involved in
hormone secretion through direct interaction
with Rim2 (Rab3 interacting molecule) (111).
The exact role of the Rap small GTPases
remains elusive from these studies.
In conclusion, cAMP regulates a wide
variety of cellular processes through three
different cAMP signaling pathways: PKA,
Epac, and ion channels. The contribution of
each of these pathways in cAMP signaling and
the exact physiological consequences for
cellular processes remain to be established, but
it is clear that it is not just PKA any more.
Unraveling the cAMP signaling network may
have important implications for treatment of
human diseases like diabetis, thrombosis,
tumorigenesis, and tumor invasion.
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SUMMARY
Background
All living creatures are built up of
cells. The smallest life forms are made out of
just one cell, like for example bacteria and
yeast. In contrast, the human body consists of
billions of cells. Every cell in the body has its
own specific location and function. Cells have
to cooperate tightly in order to make the body
function properly. There needs to be a lot of
communication between cells to coordinate all
physiological processes. Therefore, cells secrete
signal molecules called hormones. Some of
these hormones travel via the bloodstream, and
are recognized elsewhere in the body by
specific receptors, which are often located on
the outside of the cell membrane. Thousands of
receptors may exist, each recognizing a specific
molecule. A well-known example of a hormone
that may travel a large distance is insulin, which
is produced upon raised glucose levels in the
blood by the pancreatic islets of Langerhans
after a meal. Insulin is secreted into the blood
and can therefore reach cells with an insulin
receptor in the entire body. There are also
hormones that do not travel far and only reach
neighboring cells.
When a hormone is bound by a
receptor, a range of intracellular reactions may
be unleashed. For example, in the case of
insulin liver cells start producing a protein that
imports large amounts of glucose from the
blood. Subsequently, the glucose is modified
and stored by other proteins (enzymes). Other
hormones can induce cell proliferation, or
differentiation of a cell in order to make it fulfill
a specialized function in the body.
Often cells instantaneously get a
plethora of signals. It is very important that a
cell interprets these signals properly. Therefore
cells make use of networks of with each other
communicating proteins. In that way the signals
are integrated, resulting in a certain decision of
the cell, ultimately with the goal to make the
body function properly. The transmission of
hormonal signals and the communication
between the proteins in the cell is denoted
signal transduction. The smallest mistakes in
signal transduction can already result in a
catastrophe for the body. Cancer is an example
of awry communication between signal
transduction proteins, resulting in wrong
interpretation of signals and continuous cell
division.
Replication of DNA, the genetic
blueprint of a cell, is essential for a cell in order
to divide. Binding of some hormones to their
receptors may ultimately result in activation of
the process of DNA replication. This
information needs to be transferred from the
receptor on the cell surface to the cell nucleus,
where the DNA is stored. In doing so, some
receptors make use of small, intracellular
messenger molecules, called s e c o n d
messengers. Principally these can diffuse freely
throughout the cell. Calcium and cAMP (cyclic
Adenosine Mono Phosphate) are two examples
of such second messengers.
Cyclic AMP, discovered in 1956, can
bind and activate three types of proteins
(described in chapter one). The first type is
PKA (Protein Kinase A), in 1968 identified as
the first cAMP-binding protein. During
approximately twenty years it was thought that
all cellular effects of cAMP were executed
through this protein. Therefore it came as a
surprise when two other proteins were found to
be activated by cAMP, being cAMP-activated
ion-channels (proteins that form a pore in the
cell membrane through which ions can move),
and Epac.
Epac (exchange protein directly
activated by cAMP) is a so-called guanine-
nucleotide exchange factor (abbreviated as
GEF) for the protein Rap, which belongs to the
family of Ras-like small GTPases. This is an
important group of proteins involved in signal
transduction. They function as a molecular
switch, ‘off’ when they bind GDP, and ‘on’
when they bind GTP. The function of a GEF is
to replace the GDP for GTP, thereby turning the
switch on. The switch is turned off by proteins
called GAPs (GTPase Activating Proteins),
which promote processing of GTP into GDP.
Ras is the best studied small GTPase.
Ras activity is for example often required for
cell division. Small, specific changes
(‘mutations’) in Ras-like GTPases can result in
a state in which they are constantly in complex
with GTP, so they are continuously switched
on. That is also the case for Ras. Approximately
15% of all human tumors contain such a
mutated, activated Ras. The function of Rap,
however, is still elusive.
Summary
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Scope
The most important goal of this thesis
was to study the role of Epac and Rap in
cellular processes that are regulated by cAMP.
Since cAMP can activate three types of
proteins, in chapter two the development is
described of a novel, synthetic cAMP analogue,
which can exclusively bind and activate Epac,
but not PKA or ion channels. Using this
analogue the role of Epac and Rap1 was studied
in cAMP-mediated regulation of the protein Erk
(Extracellular Signal Regulated Kinase), which
is involved in for example cell proliferation.
There is a lively discussion in literature about
the role of Rap1 in this process. Using this
analogue it became clear that Epac and Rap1
are not involved in this process, but that it is
actually regulated by PKA, one of the two other
cAMP-regulated proteins.
In chapter three a novel function of
cAMP, Epac and Rap1 is described; stimulation
of integrin-mediated cell adhesion. Adhesion of
cells to their surroundings occurs via proteins
called integrins. Cell adhesion is important for
the integrity of the body, but also for fighting
infections by blood cells, or formation of a
small blood clot upon damage of a blood vessel.
Malignant tumors barely adhere to their
surroundings, allowing them to metastasize. In
contrast, thrombosis is a disease in which blood
platelets adhere too much, causing formations
of blood clots in healthy vessels. Whether Rap1
plays a role in these processes is still unclear. It
is also unclear how Rap1 increases cell
adhesion.
The experiments described in chapter
four suggest a role for cAMP, Epac, and
possibly Rap1 in activation of the protein p70
S6 kinase (p70S6K), which in turn activates the
protein S6. p70S6K and S6 are important for
cell proliferation, and possibly also survival of
cells. The mechanism of p70S6K activation by
Epac and Rap1 remains unknown.
Conclusions
As discussed in chapter five, it is
unlikely that cAMP regulates the protein Erk
through Epac and Rap1; probably this effect is
mediated by PKA. It remains possible that Epac
and Rap1 play a role cell proliferation of
specific cell types, for example by influencing
the activity of p70S6K. Furthermore, a novel
function of cAMP, Epac and Rap1 is described,
being cell adhesion. Furthermore, the result
from the development of a molecule that can
very specifically activate a single protein, Epac,
can contribute to more efficient drug design in
the future.
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SAMENVATTING
Achtergrond
Alle levende wezens zijn opgebouwd
uit cellen. De kleinste levensvormen zijn
opgebouwd uit slechts één cel, zoals
bijvoorbeeld bacteriën en gist. Het menselijk
lichaam echter bestaat uit miljarden cellen. Elke
cel heeft zijn eigen specifieke plaats en functie
in het lichaam. Cellen moeten nauwgezet
samenwerken om het lichaam juist te laten
functioneren. Er is veel communicatie nodig
tussen cellen om alle fysiologische processen te
coördineren. Daarom scheiden cellen
signaalmoleculen uit, hormonen genaamd.
Sommige van die hormonen reizen via de
bloedbaan, en worden door cellen elders in het
lichaam herkend via zogenaamde receptoren,
die meestal aan de buitenkant van de cel zitten,
op het celmembraan. Er bestaan wellicht
duizenden soorten receptoren, die elk een heel
specifiek molecuul herkennen. Een bekend
voorbeeld van zulke ver reizende moleculen is
het hormoon insuline, dat na een maaltijd als
gevolg van een hoog bloedsuikergehalte
gemaakt wordt door de eilandjes van
Langerhans in de pancreas. Insuline wordt
uitgescheiden in het bloed en kan op die manier
in het hele lichaam cellen met een insuline-
receptor bereiken. Andere hormonen reizen niet
ver, en bereiken slechts receptoren op naburige
cellen.
Als een hormoon een receptor bindt, wordt
een scala aan cellulaire reacties onteketend. In
het geval van insuline wordt bijvoorbeeld door
levercellen een eiwit gemaakt dat extra veel
glucose uit het bloed kan opnemen. Het glucose
wordt vervolgens door andere eiwitten
(enzymen) in de levercel gemodificeerd en
opgeslagen. Andere hormonen kunnen ervoor
zorgen dat een cel bijvoorbeeld gaat delen, of
zich gaat specialiseren in een bepaald celtype.
Vaak krijgen cellen een hele waaier aan
signalen tegelijk binnen. Het is erg belangrijk
dat een cel al deze signalen op de juiste wijze
interpreteert. Cellen maken daarom gebruik van
netwerken van met elkaar communicerende
eiwitten. Op die manier worden de signalen
geïntegreerd, leidend tot een bepaald besluit van
de cel, met als uiteindelijk doel het lichaam
adequaat te laten functioneren. Het overbrengen
van hormonale signalen, en de communicatie
tussen de eiwitten in de cel, wordt aangeduid
met de term signaaltransductie . Minieme
foutjes in signaaltransductie kunnen al
catastrofale gevolgen hebben voor het lichaam.
Kanker is zo’n voorbeeld van foutieve
communicatie tussen signaaltransductie-
eiwitten in een cel, met als gevolg
misinterpretatie van signalen en continue
celdeling.
Verdubbeling van DNA, de genetische
blauwdruk van de cel, is essentieel voordat een
cel kan delen. Binding van sommige hormonen
aan hun receptor resulteert uiteindelijk in
activatie van het gehele proces van DNA-
verdubbeling. Die informatie moet van de
receptor naar de celkern overgedragen worden,
waarin het DNA is opgeslagen. Sommige
receptoren maken daarbij gebruik van kleine,
intracellulaire boodschappermoleculen, second
messengers genaamd. Deze kunnen in principe
vrij door de cel diffunderen. Calcium en cAMP
(cyclic Adenosine Mono Phosphate) zijn twee
voorbeelden van zulke second messengers.
Cyclic AMP, ontdekt in 1956, kan aan drie
soorten eiwitten binden en ze daardoor
activeren (beschreven in hoofdstuk een). De
eerste soort is PKA (Protein Kinase A), in 1968
het eerste cAMP-bindende eiwit dat
geïdentificeerd werd. Gedurende ongeveer
twintig jaar dacht men dat alle cellulaire
effecten van cAMP door dit eiwit uitgevoerd
werden. Tot ieders verrassing bleken er echter
nog twee andere eiwitten geactiveerd te worden
door cAMP, namelijk cAMP-geactiveerde ion-
kanalen (eiwitten die een kleine porie in de
celmembraan vormen om ionen door te laten),
en Epac.
Epac (exchange protein directly activated
by cAMP) is een zogenaamde guanine-
nucleotide uitwisselings factor (afgekort als
GEF, voor Guanine Nucleotide Exchange
Factor) voor het eiwit Rap, dat behoort tot de
familie van de zogenaamde kleine Ras-achtige
GTPases. Dit is een belangrijke groep eiwitten
betrokken bij signaaltransductie. Ze
functioneren als een moleculaire schakelaar, en
staan ‘uit’ als ze het molecuul GDP gebonden
hebben, en ‘aan’ als ze GTP gebonden hebben.
De functie van een GEF is het vervangen van
GDP voor GTP, zodat de schakelaar aangezet
wordt. De schakelaar kan worden uitgezet
doordat een GTPase bindt aan een eiwit
genaamd GAP (GTPase Activating Protein), dat
omzetting van GTP naar GDP bevordert.
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Ras is het best bestudeerde GTPase.
Aanschakelen van Ras is vaak nodig voor
celdeling. Kleine, specifieke veranderingen
(‘mutaties’) in Ras-achtige GTPases kunnen er
echter voor zorgen dat ze altijd GTP gebonden
hebben, zodat de schakelaar altijd aanstaat. Dat
is ook voor Ras het geval. Ongeveer 15 procent
van alle humane tumoren hebben zo’n foutief
Ras dat altijd aanstaat. De functie van Rap is
echter nog onduidelijk.
Doelstelling
Het belangrijkste doel van deze
promotiestudie was het achterhalen van de rol
die Epac en Rap hebben in cellulaire processen
die door cAMP beïnvloedt worden. Omdat
cAMP drie soorten eiwitten kan activeren,
wordt in hoofdstuk twee de ontwikkeling van
een nieuw, synthetisch analoog van cAMP
beschreven, dat exclusief Epac bindt en
activeert, maar niet PKA of ion-kanalen. Met
behulp van deze analoog werd de rol bestudeerd
van Epac en Rap1 in cAMP-gestuurde regulatie
van het belangrijke eiwit Erk (Extracellular
Signal Regulated Kinase), dat betrokken is bij
onder andere celdeling. In de literatuur woedt
een levendige discussie over de rol die Rap zou
hebben in dit proces. Mede dankzij het Epac-
specifieke cAMP-analoog werd duidelijk dat
Epac en Rap geen effect hierop hebben, maar
dat het volledig afhankelijk is van een van de
twee andere cAMP-gevoelige eiwitten, namelijk
PKA.
In hoofdstuk drie wordt een nieuwe
functie voor cAMP, Epac en Rap beschreven,
namelijk stimulatie van integrine-afhankelijke
celadhesie. Adhesie van cellen aan hun
omgeving gebeurt via eiwitten die integrines
genoemd worden. Celadhesie is belangrijk voor
de integriteit van het lichaam, maar ook voor
het bestrijden van bijvoorbeeld infecties door
witte bloedcellen, of het vormen van een klein
bloedpropje als een bloedvat beschadigd is.
Kwaadaardige tumorcellen hebben nauwelijks
nog adhesie, waardoor ze kunnen uitzaaien.
Thrombose is een ziekte waarbij bloedplaatjes
juist weer te goed hechten, en daardoor gezonde
bloedvaten afsluiten. Of Rap een rol speelt in
deze processes is onbekend. Hoe Rap integrines
activeert en daarmee celadhesie stimuleert is
ook nog onduidelijk.
De experimenten beschreven in
hoofdstuk vier suggereren een rol voor cAMP,
Epac, en Rap in activatie van het eiwit p70 S6
kinase (p70S6K), dat op zijn beurt het eiwit S6
kan activeren. p70S6K en S6 zijn erg belangrijk
voor celdeling, en mogelijk ook voor het
overleven van cellen. Hoe Epac en Rap p70S6K
activeren is onbekend.
Conclusies
Zoals bediscussieerd in hoofdstuk
vijf, is het onwaarschijnlijk dat cAMP het eiwit
Erk reguleert via Epac en Rap1; waarschijnlijk
gebeurt het via PKA. Wel blijft het mogelijk dat
Epac en Rap een rol spelen in celdeling in
specifieke soorten cellen, door bijvoorbeeld de
activiteit van p70S6K te beïnvloeden. Verder is
een nieuwe functie voor cAMP, Epac en Rap1
beschreven, namelijk cel adhesie. De resultaten
uit het onderzoek naar de ontwikkeling van een
molecuul dat heel specifiek één eiwit kan
aanschakelen, namelijk Epac, kunnen een
belangrijke bijdrage leveren aan de toekomstige
wijze van ontwikkeling van farmaceutische
middelen.
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Dankwoord
Het dankwoord blijkt traditiegetrouw toch maar weer het moeilijkst en meest tijdrovendst van het
hele proefschrift. Het is bijkans onmogelijk iedereen in originele, allesomvattende bewoordingen
bedanken voor alle steun en begrip die ik vooral in de laatste twee hectische en drukke jaren heb
mogen ontvangen.
Voor een aantal mensen in het bijzonder wil ik een -bij voorbaat tekortschietende- poging wagen.
Hans, heuse rivieren van inkt vloeiden reeds ter jouwer ere. En terecht, want ik heb het in jouw lab
ongelooflijk naar mijn zin gehad. Je deur stond altijd open (en soms ging hij dicht), en je weet dat ik
daar veel steun aan heb gehad. Jouw manier van wetenschap bedrijven was een enorme eye-opener,
en ik ben er trots op bij jou te mogen promoveren. Kom je nog eens langs voor een werkbespreking
met je aio’s in San Diego? En Hermien, je hebt gelijk, Hollandse garnalen zijn de lekkerste.
Prof. Dr. Ir. Boudewijn, gaan we nou eindelijk nog eens een keer zaterdagvoetballen? Kunnen we
ons daarna bommetjevol nassen. Als één van die twee murmelende opa’s van de muppetshow was
ook jij onmisbaar, en je hebt me altijd goed bij de les gehouden. Dat je maar nog veel Nature-
artikelen en Elvis & Bambi-schilderijen op je naam mag zetten.
Jürgen (shut up you fool, I ain’t goin’ in no pool!), jij bent het soort man waar mijn moeder me
altijd voor gewaarschuwd heeft, en daar mag ik dus graag mee uithangen, want zoals Nietzsche al
zei: ‘in de hemel ontbreken alle interessante personen’. Hee, wie zie ik daar in de berm liggen
(‘wóóów!’)? Echt jammer dat we niet meer in het Kromme Zwijn kunnen zwemmen, en nadien
kleine pannenkoekjes nassen; ik zal het erg missen. And stay down! Sweet Marta ‘Maybe Rheb’
Zuccherina, it’s a miracle you’re still alive! Breathing chewing gum? Window-tossing? I hope you
don’t regret coming to our group (at least I don’t). Joost ‘Giuseppe’ Das, er is meer in het leven dan
studentes, analistes en Zita Swoon, dus trek snel je gewaden uit en stel je prioriteiten! Jammer dat ik
je geen kusjes meer kan toewuiven en liedjes voor je kan zingen. Rolandia Vulderia ssp. Velocita,
denk je aan je lieve hartje? En goed blijven doornassen! Marieken, ga je nog eens mee naar de Luie
Lakei? Amandelbroodjes smaken beter in jouw auto. Wormen-Wendy, wat was er ook weer met die
Brabantse nachten? Fried, onzel, de Achterhoek is onmundig mooi, o’ nie dan? Als ik weer eens de
wijsneus uithing wees je me gelukkig altijd fijntjes op de feiten; daarvoor ook voor jou deze
dankstond. Doe ‘t haenig an! John, is Semaia nou echt zoals je ooit zei kopje onder gegaan door de
molensteen van jouw topsalaris? We hebben een paar goeie gesprekken gehad, erg bedankt
daarvoor. Armando, hou je je onderbroek in het vervolg aan? En je moet toch echt wat aan je
gilletjes doen (bolknaksigaren helpen), en blijf voortaan met je grijpgrage klauwtjes van mijn billen!
Lydia, weet je nog dat we ooit samen pipetteerden? Toen was ik nog een beetje bang voor je, zal ik
je nu eerlijk vertellen, maar nu heb je een plekje in mijn hartje. Hou je alles goed in de gaten? Ik
hou je op de hoogte van de perikelen in de Bos-dépendance in San Diego. Paulien, you like to
bengbeng? Jammer genoeg geen mooie fik gezien (in het UMC dan hè), want vrouwen in uniform…
Bea, pas je op voor busje 12 nu ik er niet meer ben? Marion, wat hebben we lekker gebakkeleid
over je screen hè? Zet hem op! Ingrid, Amsterdam of Utrecht? Zeg niet dat ik je niet heb
gewaarschuwd, heheheh. Keidankjewel voor de cellen, en blijf zwemmen! Jun (kinase), who is Hu?
(Jintao). Mike, heb je nog een vlaagje voo’ mij? Sanne Weijzen, is het nou Nòòòtch of Notsj? Ik zal
het je eerlijk zeggen: ik was degene die al je snoep heeft opgenast. Erg lekker! Karin, waarom is die
plofkast toch zo vol? Dominique ‘von’ Brandt und Holger ‘Funkenflug’ Rehmann, men with the big
columns (does size really matter? Or is it all about how much you can elute?), when are we finally
going to finish those 100 German beers? Leo, please do not point out those bare pale-blue buttocks
to me any more, alright? It’s just not my cup of tea. Het is een vogel, ‘t is een vliegtuig,…’t is
Arjan! Ouwe vogelaar & roddelvos. Van jou kreeg ik altijd (gewenst én ongewenst, yuck!) de
laatste nieuwtjes. Hou je me op de hoogte? Marta, what was that Polish word again? (testosterone?).
You want to use my towel? It’s (almost) entirely clean! Fons, jouw rust wist me altijd te kalmeren,
en dat is ook belangrijk. Piet, ik zal niet liegen, practica geven vond ik eigenlijk niet zo heel leuk,
maar ik heb prettig met je samengewerkt. Savi, we did some nice experiments together, I wish you
lots of good luck with your new job. Taisa, are you going to find the holy grail? En de studentes
Wendy, Ankie, en Manon, drie vrouwen met alledrie een geheel eigen stijl en persoonlijkheid.
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Superbedankt voor jullie bijdrage, ik hoop dat jullie net zoveel geleerd hebben van mij als ik van
jullie.
En dan de oud-Bossers en ex-collega’s. Vadertje Geert, waar zijn je oorbellen gebleven? En wat kon
je ook weer aan het geluid van plas herkennen? Wat heb ik met je gelachen, daar gaan we mee
verder in San Diego, want ik mis je behoorlijk. Nancy, zal ik nog eens een muziekje voor je
opzetten, Scorpions of zo? Ik mis je gesprekken in onze kamer, maar ja, straks zit je weer lekker
dichtbij. Johannes, zonder jou niet dit proefschrift! Ik heb echt zin om met je te gaan surfen straks!
Bedankt voor je losbandige enthousiasme voor zowel mijn ideeën als voor het bier op de
vrijdagmiddag. Miranda, mis je de muziek? Bedankt voor je hulp, zoals jij is er geen ander. Wat kan
jij proeven doen! Waarom kom je niet terug in het Bos-lab? Kris, we shared territory for quite some
time, thanks for distracting me with your jokes, but tell me, what is a ‘Mannschaft’? Marita, you
may not have liked the music, but I enjoyed your presence in the lab. Kim, koning van de controle!
Met jouw aanstekelijke lach was het altijd aangenaam koffie drinken! En René, die andere
murmelende muppet-opa, hebben je mensen wel mondkapjes op? Wie weet zie ik je weer over een
paar jaar? Roel, in Lunetten zijn de karbonaadjes het goedkoopst hè! Saskia, Felicia, Marianne, wat
zullen jullie het rustig hebben nu ik niet meer plotsklaps kom binnenstormen. Bedankt voor alles!
Beatrice, onze communicatie was in het begin niet altijd even goed, maar dat is uiteindelijk allemaal
goedgekomen, toch? Wim, zonder jou wordt het niets in het lab, je bent het cement in de fundering,
de olie in de machine. Heel erg bedankt voor al je hulp. En natuurlijk ook Joy, Ina, Marjoleine,
Marcel, Kees, Ton, Marjan, Gerrit, allemaal bedankt! En verder alle Vlietjes, Timmersjes, en
Holsteges bedankt voor de gezelligheid. Kluivertje, blijf vlammen.
En dan nu de IBBers. Klaasch en Cécile, jullie zijn mijn beste vrienden. Hoe kan ik ooit
superlatieven verzinnen om jullie te bedanken voor al die werkelijke kostelijke diners, spellen,
avondjes uit, en immer onvoorwaardelijke steun, zonder te vervallen in armzalige cliché’s? Wat zal
ik jullie missen de komende jaren. Mag ik wel af en toe logeren in de grot van Stinkie? Merlijn,
kamergeleerde, lijk ik nou echt zoveel op Darwin? En je bent echt niet zo héél dik hoor, maar
waarom wil je toch zo graag foto’s maken van andermans vriendinnen? Ga je nog eens kip in bier
maken? Dan neem ik vast een dag vrij. Maria, een nieuw huis, een nieuwe baan, een rijbewijs, dat
gaat heel erg goed met jou! Neem Merlijn eens mee uit zijn verduisterde hol en kom langs in San
Diego, dan mag je lekker cruisen in mijn auto. Doctorandus F.J. Alda Damen (wat zitten we toch
lekker in die ivoren toren), weet je nog, die fietstocht...? De Budweisers liggen koud! Janneke, de
Scandinavische schone uit Canneto? Kom je mee met Fred? Jesse & Helma, de Lingeloop moet
even wachten, maar dan ga ik graag weer mee.
En natuurlijk de TEVA-schoenen dragende biologen. Hestertje Breij, typiste, filantroop, wie-doet-
het-nu-weer-met-wie, zeilster, visliefhebber! De rij heeft jammerlijk gefaald, maar onze vriendschap
klinkt als een klok. Vergeet je de pick-up truck en Palm Springs niet? Ik moet immers iemand
hebben om bondjes mee te smeden tegen de rest van de wereld. ‘Maden van Wurmen Paaltor’
Palthe, man van het eerste uur, trouwe vriend, drinkebroeder, jongen met die mooie ogen,
vrouwenverslinder, klusser! Op jou kan ik altijd rekenen. Nu kun jij je trapje tenminste voor een
paar jaar opbergen, en kan ik mijn mobiel weer aanzetten (heheheh). Als ik terug ben gaan we
gewoon weer verder waar we gebleven zijn. Ilse, geweldenaarster, ik heb nog eens goed gekeken,
maar die berg naar Volterra is toch wel erg lang en steil. Dat ging toch wat makkelijker met de auto.
Rikkert, in Amerika is er ook Ozzfest, dus neem je pak mee. En wil je broer misschien nog een
hond? Paul en Sung, hartstikke tof dat jullie je feest hebben vervroegd. Komen jullie ook eens bij
mij blootshands glaswol in de muur stoppen? (heheheh). Jens, let’s soon do the snakedance again in
Elvis Bar please! En Wessel: ik ben toch echt als eerste gedoopt, en Gudo: ik had als eerste met
Marcelle (en daarmee is voor allebei de kous af!).
En natuurlijk mijn familie. Mijn lieve zusje Sanne, ik ga nu even ver weg wonen, maar dan kom ik
gewoon weer terug. Kom je wel op bezoek? En wanneer wordt je eindelijk de baas van jouw
vestiging? Bedankt voor het kopen van al die kado’s voor iedereen, uitlenen van je auto, op mijn
huis passen, en al die andere dingen! Wim, het cliché wordt bevestigd, ik lijk steeds meer op jou.
Bedankt voor al je onvoorwaardelijke steun en interesse, zonder jou als voorbeeld had ik dit nooit
voor elkaar gekregen. Joke, bijna was je er niet meer, maar wat ben ik blij dat we je hebben
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teruggekregen. Jouw steun en hulp waren echt onmisbaar; je hebt me zo ontzettend veel geholpen
als ik in de put zat. Ik zal je heel erg missen in Amerika, maar de wereld is kleiner dan je denkt.
Jullie zijn het beste.
Hilde, my proud girl, we had a rough time, but it is finally going to start now! I have been looking
forward to this moment for a long time. I really cannot wait to start living with you. I am sure we
will do just fine together. You and me together... of course!
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